<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on July 2, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>No. 333- </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ekso Bionics Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>3841</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>99-0367049</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial Classification Code Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1414 Harbour Way South, Suite&nbsp;1201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Richmond, California 94804</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(510) 984-1761</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, including zip code, and telephone
number, including<BR>
area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Jack Peurach</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ekso Bionics Holdings,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1414 Harbour Way South, Suite&nbsp;1201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Richmond, California 94804</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(510) 984-1761</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, including zip code, and
telephone number, including<BR>
area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>With Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><BR>
<B>Alfredo B. D. Silva, Esq.</B><BR>
Morrison &amp; Foerster LLP<BR>
425 Market St.<BR>
San Francisco, CA 94105<BR>
 &nbsp;(415) 268-7000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed
sale to the public: <B>As soon as practicable after the effective date hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the
following box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding-right: 3pt"><FONT STYLE="font-size: 10pt">Large accelerated
filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 30%; padding-right: 3pt"><FONT STYLE="font-size: 10pt">Accelerated
filer <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt"><FONT STYLE="font-size: 10pt">Non-accelerated filer
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding-right: 3pt"><FONT STYLE="font-size: 10pt">Smaller reporting company
<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt"><FONT STYLE="font-size: 10pt">Emerging growth company
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CALCULATION
OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of Each Class of Securities to be Registered</B></FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount to be Registered<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed Maximum Offering Price Per Share<SUP>(3)</SUP></B></FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed Maximum Aggregate Offering Price</B></FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount of Registration Fee</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock, $0.001 par value per share <SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">873,852</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$6.91</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$6,038,317.32</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">$783.77</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include
such indeterminate number of additional shares of common stock, $0.001 par value per share (&ldquo;Common Stock&rdquo;) as may
be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents the resale of shares of Common Stock issuable upon
the exercise of certain warrants issued in private placements described herein. Pursuant to Rule 416(a) under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), this Registration Statement shall also cover an indeterminate amount and
number of each identified class of the identified securities as may be issued upon conversion, exchange, exercise or settlement
of any other securities that provide for such conversion, exchange, exercise or settlement.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of computing the amount of
the registration fee for the shares of common stock issuable upon exercise of warrants being registered in accordance with Rule
457(c) under the Securities Act based upon the average of the high and low prices for a share of the registrant&rsquo;s common
stock as reported on The Nasdaq Capital Market on June 25, 2020, which date is within five business days prior to the date of the
filing of this registration statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information in this
prospectus is not complete and may be changed. The selling stockholders may not sell these securities pursuant to this prospectus
until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not
permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION, DATED
JULY 2, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1549084|000110465920073591|tm2022583d1_s3sp2img01.jpg" STYLE="height: 126px; width: 162px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>873,852 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuable upon Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo;
of up to 873,852 shares of our common stock they may acquire upon the exercise of warrants issued on June 10, 2020, or the June
2020 Warrants. We issued the June 2020 Warrants to the selling stockholders in a private placement financing we completed in June&nbsp;10,
2020. We are registering the applicable shares of our common stock to provide the selling stockholders with freely tradable securities.
The registration of the shares of our common stock covered by this prospectus does not necessarily mean that any shares of our
common stock will be sold by any of the selling stockholders, and we cannot predict when or in what amounts any of the selling
stockholders may sell any of our shares of common stock offered by this prospectus. The prices at which the selling stockholders
may sell the shares of our common stock will be determined by prevailing market prices or at prices that may be obtained in negotiated
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not selling any shares of our common stock under this
prospectus and will not receive any proceeds from any sale or disposition by the selling stockholders of the shares of our common
stock covered by this prospectus. However, we will receive proceeds in connection with the applicable exercise price of the June
2020 Warrants to purchase shares of our common stock, which, if exercised in cash with respect to all June 2020 Warrants, would
result in gross proceeds to us of approximately $4.5 million, but under certain circumstances such warrants may be exercised via
cashless exercise. In addition, we will pay all fees and expenses incident to the registration of the resale of shares of our common
stock under this prospectus. The selling stockholders from time to time may offer and sell the shares of our common stock held
by them directly or through one or more underwriters, broker-dealers or agents on terms to be determined at the time of sale, as
described in more detail in this prospectus under &ldquo;Plan of Distribution.&rdquo; No shares of our common stock may be sold
without delivery of this prospectus describing the method and terms of the offering of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
listed and trades on The Nasdaq Capital Market under the symbol &ldquo;EKSO.&rdquo; The last reported sale price of our common
stock on The Nasdaq Capital Market on June 30, 2020 was $8.40 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities involves a high degree of risk.
Before making any investment decision, you should carefully review and consider all the information in this prospectus and the
documents incorporated by reference herein and therein, including the risks and uncertainties described under &ldquo;Risk Factors&rdquo;
beginning on page 6 of this prospectus and the risk factors incorporated by reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is , 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_002">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_003">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">4</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_004">THE OFFERING</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_005">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">8</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_007">SELLING STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">9</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_008">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">11</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_009">DESCRIPTION OF COMMON STOCK TO BE REGISTERED</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">13</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_010">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">14</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_011">EXPERTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">14</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_013">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">14</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_015">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015">15</A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the resale by the selling stockholders identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo; from
time to time, of up to an aggregate of 873,852 shares of our common stock, par value $0.001 per share, issuable upon exercise of
certain common stock purchase warrants. As described below under &ldquo;Prospectus Summary&mdash;Private Placement Offering,&rdquo;
the shares of our common stock registered by this prospectus are issuable upon exercise of June 2020 Warrants to purchase up to
873,852&nbsp;shares of our common stock for an exercise price of $5.18 per share issued on June 10, 2020, all of which are exercisable
by the selling stockholders. We will not receive any proceeds from the sale of shares of common stock offered hereby by the selling
stockholders. The registration statement containing this prospectus, including the exhibits to the registration statement, provides
additional information about us and the securities offered under this prospectus. The registration statement, including the exhibits,
can be read on the SEC&rsquo;s website or at the SEC offices mentioned under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information contained or incorporated by reference in this prospectus. We are not selling any shares of our common stock
under this prospectus, and we have not authorized any other person to provide you with different information. If anyone provides
you with different information, you should not rely on it. This prospectus is not an offer to sell these securities and it is
not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume
that the information contained in this prospectus and the documents incorporated by reference herein and therein are accurate
only as of the date such information is presented. Neither the delivery of this prospectus nor any sale made in connection with
this prospectus, under any circumstances, create any implication that there has been no change in our affairs since the date of
this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus may
be supplemented from time to time to add, update or change information in this prospectus. Any statement contained in this prospectus
will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus
modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus is only
as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise expressly
stated or the context otherwise requires, references in this prospectus to (i) &ldquo;Ekso Bionics,&rdquo; &ldquo;the Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Ekso Bionics Holdings, Inc., a Nevada corporation, and (ii)&nbsp;&ldquo;common
stock&rdquo; refer to shares of the Company&rsquo;s common stock, $0.001 par value per share. When we refer to &ldquo;you,&rdquo;
we mean the potential holders of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and
the information incorporated by reference herein contain references to our trademarks and to trademarks belonging to other entities,
which are protected under applicable intellectual property laws. Solely for convenience, our trademarks and tradenames referred
to in this prospectus supplement appear without the &reg; and &trade; symbol, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor
to these trademarks and tradenames. All trademarks, service marks and trade names included or incorporated by reference into this
prospectus are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, as
well as the information incorporated by reference herein and therein, contain certain statements that constitute &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and
within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E
of the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). All statements, other than statements of historical facts,
included or incorporated in this prospectus regarding our strategy, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as &ldquo;aim,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;assume,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;due,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;goal,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;objective,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;positioned,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo;
and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms
or other comparable terminology, although not all forward-looking statements contain these identifying words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
included or incorporated by reference in this prospectus include, for example, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to obtain adequate financing to fund operations and to develop or enhance our technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the scope, scale and duration of the impact of outbreaks of a pandemic disease, such as COVID-19
(coronavirus);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to obtain or maintain regulatory approval to market our medical devices;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to complete clinical trials on a timely basis and that completed clinical trials will
be sufficient to support commercialization of our products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the anticipated timing, cost and progress of the development and commercialization of new products
or services, and improvements to our existing products, and related impacts on our profitability and cash position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to effectively market and sell our products and expand our business, both in unit sales
and product diversification;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to achieve broad customer adoption of our products and services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to achieve anticipated synergies and benefits of, and maintain our current and future
collaborations, joint ventures or partnerships;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">existing or increased competition;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">rapid changes in technological solutions available to our markets;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">volatility with our business, including long and variable sales cycles, which could have a negative
impact on our results of operations for any given quarter or fiscal year;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in our domestic or international sales and operations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to obtain or maintain patent protection for our intellectual property;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the scope, validity and enforceability of our and third party intellectual property rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">significant government regulation of medical devices and the healthcare industry;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to unwind our role with the joint-venture in China in accordance with regulatory requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">outbreaks of a pandemic disease, such as COVID-19 (coronavirus);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our customers&rsquo; ability to get third party reimbursement for our products and services associated
with them; our failure to implement our business plan or strategies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our early termination of leases, difficulty filling vacancies or negotiating improved lease terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to retain or attract key employees;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">stock volatility or illiquidity;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to maintain adequate internal controls over financial reporting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the use of proceeds from, the timing of, and our ability to successfully complete this offering;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">overall economic and market conditions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements are
based on current expectations, assumptions, assessments, estimates, forecasts and projections about our business and the industry
in which we operate made by our management in light of its experience and its perception of historical trends, current conditions,
expected future developments and other factors our management believes to be appropriate. These forward-looking statements are
subject to a number of known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as amended,
and our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2020 as such risk factors may be amended, updated or modified
periodically in our reports filed with the SEC, and the financial data and related notes and the reports incorporated by reference
in this prospectus, for further information on these and other risks affecting us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Potential investors
are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak
only as of the date hereof and as of the dates indicated in these statements. Except as required by law, we assume no obligation
to update or revise these forward-looking statements for any reason, even if new information becomes available in the future, except
as required by law. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions
of future events. You should, however, review the factors and risks we describe in the reports we will file from time to time with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) after the date of this prospectus. See &ldquo;Where You Can Find
More Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 3pt; border: Black 1pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
certain information about us, this offering and the other information appearing elsewhere in this prospectus and in the documents
we incorporate by reference herein. This summary is not complete and does not contain all of the information that you should consider
before investing in our securities. To fully understand this offering and its consequences, you should read this entire prospectus
carefully, including the information set forth under the caption &ldquo;Risk Factors&rdquo; on page 6 in this prospectus and under
similar captions in the documents incorporated by reference herein, before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We design, develop
and sell exoskeleton technology to augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets
and can be used both by able-bodied persons as well as by persons with physical disabilities. We have sold, rented or leased devices
that (i)&nbsp;enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate, and
in some cases, to walk again, (ii)&nbsp;assist individuals with a broad range of upper extremity impairments, and (iii)&nbsp;allow
industrial workers to perform difficult repetitive work for extended periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our EksoVest is an
upper body exoskeleton that elevates and supports a worker&rsquo;s arms to assist them with tasks ranging from chest height to
overhead. In 2020, we are focusing on increasing sales of the EksoVest and the support arm, EksoZeroG, by pursuing alternative
channels, such as rental agreements with construction equipment and heavy tool providers and working with automotive and related
manufacturers to roll out our product(s) globally within their assembly operations. In addition, we believe that there is additional
mid-to-long-term potential in the industrial markets, and accordingly, we will continue our development efforts to expand our EksoWorks
product offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the commercial
opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic
and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements
have become ubiquitous in peoples&rsquo; everyday lives. We believe that we have learned how to integrate these existing technologies
and wrap the result around a human being efficiently, elegantly and safely, supported by an industry-leading intellectual property
portfolio. We further believe that we can do so across a broad spectrum of applications, from persons with lower limb paralysis
to able-bodied users.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional details
of these programs and related strategic agreements are contained in our Annual Report on Form 10-K for the year ended December&nbsp;31,
2019, as amended, and our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><B>Private Placement Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 7, 2020, we entered into a securities purchase agreement
with certain purchasers, each of whom is an institutional and accredited investor, and on June 10, 2020, or the closing date, we
completed our offer and sale to certain accredited investors of (i) 1,747,704 shares of our common stock at a purchase price of
$4.5145 per share, which were sold in a registered direct offering, and (ii) June 2020 Warrants to purchase up to an aggregate
of 873,852 shares of our common stock, representing 50% of the shares of the common stock purchased in the registered direct offering,
which were sold in a concurrent private placement. The June 2020 Warrants had an initial exercise price of $5.18 per share (subject
to adjustment as set forth therein), were immediately exercisable and expire five and one-half years from the issue date, or on
December 10, 2025. All of the June 2020 Warrants contain certain ownership limitations that may restrict their exercise, as described
under the caption &ldquo;Selling Stockholders&rdquo; in this prospectus. In addition, all such warrants are exercisable on a cashless
basis if there is no effective registration statement registering, or no current prospectus available for, the resale of the shares
of common stock underlying the June 2020 Warrants by the holder. Pursuant to the stock purchase agreement, we agreed to file this
registration statement on Form S-1 with respect to the resale by the purchasers of the shares of common stock underlying the June
2020 Warrants issuable upon exercise of the June 2020 Warrants within 30 calendar days of the date of the securities purchase agreement,
or by July 7, 2020, and to use commercially reasonable efforts to cause such registration statement to become and remain effective.
Only the 873,852 shares issuable upon exercise of the June 2020 Warrants described in clause (ii) above are registered for resale
pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
are located at 1414 Harbour Way South, Suite 1201, Richmond, California. Our telephone number is (510) 984-1761, and our website
address is www.eksobionics.com. Our official Twitter account is @EksoBionics. The information on or accessible through our website
or our Twitter account does not constitute part of this prospectus supplement or the accompanying prospectus and should not be
relied upon in connection with making any investment in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;24,
2020, we effected a 1-for-15 reverse split of our common stock. As a result of the reverse stock split, every 15 shares of issued
and outstanding common stock were converted into one share of issued and outstanding common stock. We previously effected a 1-for-7
reverse stock split on May&nbsp;4, 2016. Unless otherwise indicated, all references to share and per share amounts in this prospectus
supplement, reflect the reverse stock splits. Our common stock is listed on Nasdaq Capital Market under the symbol &ldquo;EKSO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 3pt; border: Black 1pt solid">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>THE OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Shares of common stock being offered by the selling stockholders:</TD>
    <TD STYLE="width: 50%; text-align: justify">Up to 873,852 shares of common stock issuable upon exercise
of June 2020 Warrants. See &ldquo;Selling Stockholders&rdquo; beginning on page 10 of this prospectus.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Use of proceeds:</TD>
    <TD STYLE="text-align: justify">All proceeds from the sale of the shares of common stock under this prospectus will be for the account of the selling stockholders. We will not receive any proceeds from the sale of our shares of common stock offered pursuant to this prospectus. Any net proceeds received by us from the exercise of the June 2020 Warrants will be used for general corporate purposes, which may include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.&nbsp;See the section entitled &ldquo;Use of Proceeds&rdquo; in this prospectus.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Nasdaq Capital Market symbol:</TD>
    <TD STYLE="text-align: justify">EKSO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Listing:</TD>
    <TD STYLE="text-align: justify">Our common stock is listed and trades on The Nasdaq Capital Market. There is no established trading market for the June 2020 Warrants and we do not intend to list such warrants on any exchange or other trading or quotation system.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dividend policy:</TD>
    <TD STYLE="text-align: justify">We do not anticipate paying any cash dividends on our common stock in the foreseeable future.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Risk factors:</TD>
    <TD STYLE="text-align: justify">Investing in our securities involves a high degree of risk.
Before you decide to invest in our common stock, you should carefully read this prospectus in its entirety and carefully consider
the risks and uncertainties described in &ldquo;Risk Factors&rdquo; beginning on page 6 of this prospectus and in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2019, as amended, and our Quarterly Reports on Form 10-Q for the quarter ended
March 31, 2020, as such risk factors may be amended, updated or modified periodically in our reports filed with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;), and the financial data and related notes and the reports incorporated by reference
herein and therein.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in shares
of our common stock involves significant risks. You should carefully consider the specific risks described below, as well as the
other information contained in this prospectus and the other documents incorporated by reference, before making an investment decision.
Please see the risk factors under the heading &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form 10-K, as amended,
and as revised or supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our most recent Annual
Report on Form 10-K, each of which are on file with the SEC and are incorporated by reference in this prospectus. Before making
an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference
in this prospectus. See the sections of this prospectus entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Documents By Reference.&rdquo; Any of the risks we describe below or in the information incorporated herein by reference
in this prospectus could cause our business, financial condition or operating results to suffer. The market price of our common
stock could decline if one or more of these risks and uncertainties develop into actual events. You could lose all or part of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to this
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience future dilution as a result of future
equity offerings.</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional capital, we
may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share
that is equal to or greater than the price per share that you pay for the shares offered by this prospectus, and investors purchasing
shares or other securities in future offerings could have rights superior to existing stockholders. A significant portion of our
total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop
significantly, even if our business is doing well.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a significant number of shares of our common
stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number of shares
of our common stock, or other equity-related securities in the public markets, or the perception that such sales could occur, could
depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.
We have registered for sale shares of common stock issuable from time to time upon the exercise of certain outstanding warrants
to purchase common stock, including: (i)&nbsp;warrants to purchase 106,896 shares of common stock with an exercise price of $41.25
per share, expiring on December&nbsp;23, 2020 (the &ldquo;2015 Warrants&rdquo;), (ii)&nbsp;warrants to purchase 444,444 shares
of common stock with an exercise price of $3.52 per share, expiring on May&nbsp;24, 2024 (the &ldquo;May&nbsp;2019 Warrants&rdquo;),
(iii)&nbsp;warrants to purchase 51,836 shares of common stock with an exercise price of $8.44, expiring on December&nbsp;18, 2025
(the &ldquo;December&nbsp;2019 Placement Agent Warrants&rdquo;) and (iv)&nbsp;warrants to purchase 555,763 shares of common stock
with an exercise price of $8.10, expiring on June&nbsp;21, 2025 (the &ldquo;December&nbsp;2019 Warrants&rdquo; and, together with
the 2015 Warrants, the May&nbsp;2019 Warrants, and the December&nbsp;2019 Placement Agent Warrants, the &ldquo;Registered Warrants&rdquo;).
Assuming that all the Registered Warrants are exercised in full, based upon the shares outstanding as of March&nbsp;31, 2020, we
will have outstanding an aggregate of 7,002,381 shares of common stock, assuming no exercise of outstanding stock options, no settlement
of restricted stock units, no exercises of any other warrants to purchase our common stock and no other sales or issuances of our
common stock. A substantial majority of the outstanding shares of our common stock are, and all of the shares sold upon exercise
of the Registered Warrants will be, freely tradable without restriction or further registration under the Securities Act, unless
these shares are owned or purchased by &ldquo;affiliates&rdquo; as that term is defined in Rule&nbsp;144 under the Securities Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have also registered all
of the shares of common stock that we may issue pursuant to the exercise of outstanding stock options and settlement of restricted
stock units granted under our Amended and Restated 2014 Equity Incentive Plan, or 2014 Incentive Plan, and all of the shares of
common stock that we may issue under our Amended and Restated 2014 Equity Incentive Plan Employee Stock Purchase Plan, or ESPP.
As of March&nbsp;31, 2020, 349,215 shares of our common stock were reserved for issuance of future awards under our 2014 Incentive
Plan and 500,000 shares of common stock were reserved for issuance under our ESPP. As a result, these shares can be freely sold
in the public market upon issuance, subject to restrictions related to affiliate sales under the securities laws. Additionally,
as of March&nbsp;31, 2020, 13,333 shares of common stock were issuable upon the exercise of outstanding warrants other than the
Registered Warrants at an exercise price of $22.50 per share. These shares will only be freely tradable after issuance if registered
in the future under the Securities Act or in reliance on any available exemptions from the registration requirement of the Securities
Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the May&nbsp;2019 Warrants contain
price-based anti-dilution adjustment provisions. Future anti-dilution adjustments to such warrants may result in substantial additional
dilution to existing stockholders and may depress the market price of our common stock. The issuance of the shares of common stock
underlying these warrants, or perception that issuance may occur, will have a dilutive impact on other stockholders and could have
a material negative effect on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not currently intend to pay dividends on our common
stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the present time, we intend to use available
funds to finance our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors
(subject to any contractual restrictive covenants, such those in our loan agreement with the Western Alliance Bank), we have no
current intention of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all,
only from potential increases in the price of our common stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to our Business</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The recently announced Committee on Foreign Investment
in the United States determination requires us to terminate our China JV, which will adversely impact our ability to expand operations
globally and in particular, in China.</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&nbsp;30, 2019, we and our wholly-owned
subsidiary, Ekso Bionics, Inc. (&ldquo;Ekso US&rdquo;), entered into an agreement with Zhejiang Youchuang Venture Capital Investment
Co., Ltd (&ldquo;ZYVC&rdquo;) and another partner (collectively, the &ldquo;JV Partners&rdquo;), as amended by the Amendment to
the Joint Venture Agreement, dated April&nbsp;30, 2019 (as amended, the &ldquo;JV Agreement&rdquo;) to establish Exoskeleton Intelligent
Robotics Co. Limited (the &ldquo;China JV&rdquo;), a Chinese limited liability company designed to develop and serve the exoskeleton
market in China and other Asian markets and to create a global exoskeleton manufacturing center in the Zhejiang Province of China.
In connection with the China JV, the JV Partners and their affiliates agreed to purchase an aggregate of 204,499 shares of our
common stock at a price per share equal to $24.45, for aggregate proceeds to us of $5.0&nbsp;million.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed, following U.S. governmental
inquiries regarding the China JV, the Company and the China JV formally submitted a joint voluntary notice to Committee on Foreign
Investment in the United States (&ldquo;CFIUS&rdquo;) in December&nbsp;2019 to review the transaction. CFIUS subsequently inquired
about our legacy work for the U.S. government as well as technology transfers and other aspects of the China JV and, in February&nbsp;2020,
imposed interim measures to mitigate identified concerns pending completion of its investigation. These measures temporarily suspended
the Company&rsquo;s contributions to the China JV and other integration activities for the China JV.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&nbsp;19, 2020, we received notice
from CFIUS in connection with its review of the Company&rsquo;s and the JV Partners&rsquo; investment the China JV. The notice
states that CFIUS&rsquo;s prior national security concerns regarding the JV could not be mitigated and, in connection with its
determination, CFIUS presented the Company and the JV Partners with a draft National Security Agreement (&ldquo;NSA&rdquo;), which
will, among other things, require the termination of the Company&rsquo;s role with the China JV. The Company intends to work cooperatively
with the JV Partners and CFIUS to finalize the terms of the NSA. In the event the parties cannot agree on the NSA&rsquo;s terms,
CFIUS will refer the matter to the President of the United States, who very likely will order the termination of the China JV and
the divestment of the shares acquired in connection with the China JV, per the President&rsquo;s authority under the Defense Production
Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the termination of the China JV
is not expected to have a material impact on the Company&rsquo;s operations during the remainder of 2020, if the Company is unable
to efficiently identify and partner with other global manufacturing sources and Asia-based distributors, we may not be able to
reduce the cost of manufacturing our products or increase sales in Asia in a cost-effective manner, which could have a material
adverse effect on our financial results in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive
any proceeds from the sale of the shares of our common stock issuable upon exercise of the June 2020 Warrants to purchase shares
of our common stock by the selling stockholders from time to time pursuant to this prospectus. The proceeds from the offering are
solely for the account of the selling stockholders. See &ldquo;Selling Stockholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will, however,
receive proceeds from any cash exercise of the June 2020 Warrants. If the June 2020 Warrants were exercised in cash with respect
to all of the 873,852 shares of common stock subject thereto, we would receive gross proceeds of approximately $4.5 million. We
cannot predict when or if the June 2020 Warrants will be exercised, and it is possible that such warrants may expire and never
be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Any
net proceeds received by us from the exercise of the June 2020 Warrants will be used for general corporate purposes, which may
include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities
expansion, and to meet working capital needs. We expect from time to time to evaluate the acquisition of businesses, products and
technologies for which a portion of the net proceeds may be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">This
represents our best estimate of the manner in which we will use any net proceeds we receive from the exercise of the June 2020
Warrants based on the status of our business, but we have not reserved or allocated amounts for specific purposes and we cannot
specify with certainty how or when we would use any net proceeds. The amounts and timing of our actual expenditures may vary significantly
depending on numerous factors, including the amount and timing of the proceeds received from the exercise of the June 2020 Warrants
and progress with the achievement of our corporate goals. Expenditures will also depend upon the establishment and maintenance
of manufacturing and supply chains, the availability of additional financing and other factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">We
will have broad discretion in the application of any net proceeds we receive, and we could use any such proceeds for purposes other
than those currently contemplated. Pending the use of the net proceeds from this offering as described above, we may invest the
net proceeds in a variety of capital preservation investments, including short- and intermediate-term, interest-bearing obligations,
investment-grade instruments or U.S. government securities. Investors will be relying on the judgment of our management regarding
the application of the proceeds of any sale of shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>SELLING STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus covers
an aggregate of up to 873,852 shares of our common stock that may be sold or otherwise disposed of by the selling stockholders
identified herein. Such shares are issuable to the selling stockholders upon the exercise of June 2020 Warrants we issued and
sold to the selling stockholders in a private placement transaction, as described above under &ldquo;Prospectus Summary&mdash;Private
Placement Offering.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we refer to the
selling stockholders in this prospectus, we mean those persons listed in the table below, as well as the permitted transferees,
pledgees, donees, assignees, successors and others who later come to hold any of the selling stockholders&rsquo; interests other
than through a public sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may from time to time offer and sell pursuant to this prospectus any or all of the shares of common stock set forth in the following
table. There is no requirement for the selling stockholders to sell their shares, and we do not know when, or if, or in what amount
the selling stockholders may offer the shares of common stock for sale pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
identified below may have sold, transferred or otherwise disposed of some or all of their shares since the date on which the information
in the following table is presented in transactions exempt from or not subject to the registration requirements of the Securities
Act. Information concerning the selling stockholders may change from time to time and, if necessary, we will supplement this prospectus
accordingly. We are unable to confirm whether the selling stockholders will in fact sell any or all of their shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge and
except as noted below, none of the selling stockholders has, or within the past three years has had, any material relationships
with us or any of our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Selling Stockholder <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares of Common Stock Owned Prior to Offering <SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares Owned After Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent of Shares of Common Stock Owned After Offering (%) <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(4)</SUP></FONT></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 32%"><FONT STYLE="font-size: 10pt">Anson Investments Master Fund LP <SUP>(5)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-size: 10pt">499,109</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">276,886</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">222,223</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">2.56</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Armistice Capital Master Fund Ltd.<SUP>(6)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">653,414</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">320,080</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">333,334</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.84</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Intracostal Capital, LLC<SUP>(7)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">276,886</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">276,886</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;&ndash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;&ndash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 1%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">The information in this table and the related notes is based upon information supplied by the selling
stockholders, including reports and amendments thereto filed with the SEC on Schedules 13G.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Represents the total number of shares of our common stock owned by or issuable to the relevant
selling stockholder as of the date of this prospectus, without regard to ownership limitations set forth in the applicable agreements
or other documents relating to such shares and without regard to initial exercise or conversion dates of exercisable or convertible
securities owned by such selling stockholder, including (i) all of the shares offered by this prospectus, and (ii) to our knowledge,
all other securities held by such selling stockholder as of the date of this prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Assumes that none of the June 2020 Warrants that are exercisable for the shares of our common stock
offered by this prospectus have been sold or otherwise transferred prior to the date of this prospectus in transactions exempt
from the registration requirements of the Securities Act. All June 2020 Warrants contain certain beneficial ownership limitations,
which provide that a holder of the June 2020 Warrants will not have the right to exercise any portion of its June 2020 Warrants
if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock
outstanding immediately after giving effect to such exercise, provided that upon at least 61 days prior notice to us, a holder
may increase or decrease such limitation up to a maximum of 9.99% of the number of shares of common stock outstanding. However,
the number of shares of common stock reflected in this column as owned by each selling stockholder does not take into account such
beneficial ownership limitations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">The percentage of beneficial ownership is based on 7,811,103
shares outstanding as of July 1, 2020, plus the 873,852 shares issuable upon exercise of the June 2020 Warrants, assuming full exercise of such warrants. The number of shares of common stock reflected in this column as owned by each selling stockholder
assumes that (a) all shares to be sold in this offering are sold, and (b) after the date of this prospectus and prior to completion
of this offering, none of the selling stockholders (i)&nbsp;acquires additional shares of our common stock or other securities
or (ii)&nbsp;sells or otherwise disposes of shares of our common stock or other securities held by such selling stockholders as
of the date hereof and not offered hereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Anson Advisors Inc. and Anson Funds Management LP are the co-investment advisers of Anson Investments
Master Fund LP, and, in such capacity, may be deemed to have voting and dispositive power over the securities held for the account
of Anson Investments Master Fund LP. Bruce Winson is the managing member of Anson Management GP LLC, which is the general partner
of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Messrs. Winson, Kassam and Nathoo
each disclaim beneficial ownership of this common stock, except to the extent of their pecuniary interest therein. The principal
business address of Anson Investments Master Fund LP is Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George
Town, Grand Cayman KY1-9008, Cayman Islands.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. and Steven
Boyd is the managing member of Armistice Capital, LLC, and, in such capacity, Armistice Capital, LLC and Steven Boyd may be deemed
to have voting and dispositive power over the securities held for the account of Armistice Capital Master Fund Ltd. Armistice Capital,
LLC and Steven Boyd disclaim beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest
therein. The address for Armistice Capital, LLC is 501 Madison Avenue, 7th Floor, New York, NY 10022.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Mitchell P. Kopin and Daniel B. Asher, are each managers of Intracoastal Capital LLC, and, in such
capacity, may be deemed to have voting and dispositive power over the securities held for the account of Intracoastal Capital LLC.
The address for Intracoastal Capital LLC is 2211A Lakeside Drive, Bannockburn, IL 60015.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each selling stockholder
of the shares of common stock and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their shares of our common stock included in the registration statement of which this prospectus is a part, on The Nasdaq
Capital Market or any other stock exchange, market or trading facility on which the shares of common stock are traded or in private
transactions. These sales may be in one or more transactions at fixed prices, at prevailing market prices at the time of the sale,
at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may sell such shares directly
or through one or more underwriters, broker-dealers or agents. If the shares of our common stock are sold through underwriters
or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent&rsquo;s commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A selling stockholder
may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchases;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell the shares as agent but may position
and resell a portion of the block as principal to facilitate the transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">settlement of short sales;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">in transactions through broker-dealers that agree with the selling stockholder to sell a specified
number of such shares at a stipulated price per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a combination of any such methods of sale; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may also resell all or a portion of the shares of common stock under Rule 144 under the Securities Act or any other exemption from
registration, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged
by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of our common stock, from
the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the sale of the shares of common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course
of hedging the positions they assume. The selling stockholders may also sell common stock short and deliver these shares of common
stock to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these shares
of common stock. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial
institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institutions
of shares of common stock offered by this prospectus, which shares of common stock such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may pledge or grant a security interest in some or all of the June 2020 Warrants or shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock from time to time pursuant to this prospectus or other applicable provision of the Securities Act, amending, if necessary,
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under
this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which
case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the shares of common stock and that there is no underwriter
or coordinating broker acting in connection with the proposed sale of the shares of common stock offered hereby by the selling
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay all fees and expenses of the registration of the
shares of common stock, estimated to be approximately $65,000 in total, including, without limitation, SEC filing fees and expenses
of compliance with state securities or &ldquo;blue sky&rdquo; laws; provided, however, that a selling stockholder will pay all
underwriting discounts and selling commissions, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock offered
hereby will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for
sale in such state or an exemption from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the shares of common stock offered hereby may
not simultaneously engage in market making activities with respect to the shares of common stock for the applicable restricted
period, as defined by Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be
subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may
limit the timing of purchases and sales of the shares of common stock by the selling stockholders or any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once sold under the
registration statement, of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands
of persons other than our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>DESCRIPTION OF COMMON STOCK TO BE REGISTERED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue 141,428,571 shares
of common stock, par value $0.001 per share. On July 1, 2020, we had 7,811,103 shares of common stock outstanding and approximately
202 stockholders of record. In this offering, the selling stockholders are offering up to 873,852 shares of our common stock they
 may acquire upon the exercise of June 2020 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary of certain provisions
of our common stock does not purport to be complete. You should refer to our articles of incorporation and our bylaws, both of
which are included as exhibits to the registration statement of which this prospectus is a part. The summary below is also qualified
by provisions of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividends.&nbsp;</I>The holders of outstanding
shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends
of such times and in such amounts as the board from time to time may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting</I>. Holders of common stock are
entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the
election of directors then standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Pre-emptive Rights, Redemption, Conversion
and Sinking Fund Provisions</I>. The common stock is not entitled to pre-emptive rights and is not subject to conversion, redemption
or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Rights.&nbsp;</I>Upon liquidation,
dissolution or winding up of our Company, the assets legally available for distribution to stockholders are distributable ratably
among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims
of creditors. Each outstanding share of common stock is duly and validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Transfers</I>. There are no restrictions
on the transfer of our common stock except such restrictions as may be imposed by applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Description of Outstanding June 2020 Warrants to Purchase
Shares of Common Stock pursuant to which the Offered Shares of Common Stock May Be Issued</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
summarizes the material terms and provisions of the June 2020 Warrants. &nbsp;As of July&nbsp;1,&nbsp;2020, there were 873,852
June 2020 Warrants outstanding to purchase shares of common stock. The June 2020 Warrants were immediately exercisable on June
10, 2020&nbsp;and remain exercisable until the 5.5-year anniversary of their date of issuance, but not thereafter. The June 2020
Warrants are exercisable at an exercise price of $5.18 per share, which exercise price in each case, along with the number of shares
of common stock issuable upon the exercise of such warrants, will be subject to adjustment for stock splits, reverse splits, stock
dividends, and similar capital transactions as described in the June 2020 Warrants. A holder of June 2020 Warrants will have the
right to exercise such warrants on a &ldquo;cashless&rdquo; basis if at the time of exercise, there is no effective registration
statement registering, or no current prospectus available for, the resale of the shares of common stock underlying the June 2020
Warrants by the holder. A holder of June 2020 Warrants will not have the right to exercise any portion of its June 2020 Warrants
if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the investor&rsquo;s election),
of the number of our shares of our common stock outstanding immediately after giving effect to such exercise; provided, however,
that upon at least 61 days prior notice to us, a holder may increase or decrease such limitation up to a maximum of 9.99% of the
number of shares of common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the June
2020 Warrants have the right to participate in any rights offering, dividend or distribution of assets together with the holders
of our common stock on an as-exercised basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transfer Agent and Registrar</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our shares of common stock is VStock Transfer, LLC. Its address is 18 Lafayette Place, Woodmere, New York 11598
and its telephone number is (212) 828-8436.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trading Market</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common
stock are listed on The Nasdaq Capital Market under the symbol &ldquo;EKSO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the
common stock offered by this prospectus will be passed upon for us by Snell &amp; Wilmer L.L.P., San Francisco, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OUM&nbsp;&amp; Co.
LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form
10-K for the year ended December 31, 2019, as set forth in their report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on OUM&nbsp;&amp;
Co. LLP's report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A>WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC a registration statement under the
Securities Act that registers the securities offered hereby. The registration statement, including the exhibits and schedules attached
thereto and the information incorporated by reference therein, contains additional relevant information about the securities and
our company, which we are allowed to omit from this prospectus pursuant to the rules and regulations of the SEC. In addition, we
file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to
the public over the Internet at the SEC&rsquo;s website at www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish
to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These
filings will be available free of charge as soon as reasonably practicable after we electronically file such material with, or
furnish it to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a web site
at www.eksobionics.com. Information contained on our website is neither incorporated by reference into this prospectus nor a part
hereof or any other document we file with or furnish to the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A>INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to
incorporate by reference into this prospectus certain information contained in other documents and reports that we file with it,
which means that we can disclose important information to you by referring you to such documents and reports. The information incorporated
by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically
update and supersede information contained in this prospectus. We incorporate by reference the documents listed below that we have
previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed &ldquo;filed&rdquo; pursuant to the General
Instructions of Form 8-K):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2019 filed with the
SEC on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/ekso1231201910-k.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">February&nbsp;27, 2020</A>, and amended on Form&nbsp;10-K/A filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000154908420000010/ekso1231201910-ka.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">April&nbsp;28, 2020</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2020, filed with the SEC
on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1549084/000154908420000016/ekso-20200331.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">April&nbsp;30, 2020</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our Current Reports on Form 8-K, filed with the SEC on &nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920003038/tm201778d1_8k.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">January
                                                                  10, 2020</A>&nbsp;(Item 8.01 only),&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920005949/tm203792d1_8k.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">January&nbsp;22,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920035326/tm2013063d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;18,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920037753/tm2013624d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;24,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920041870/tm2014387d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;1,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000154908420000008/ekso-42020208xk.htm" STYLE="-sec-extract: exhibit">April&nbsp;24,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1549084/000154908420000019/ekso-20200511.htm" STYLE="-sec-extract: exhibit">May&nbsp;15,
                                                                  2020</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_8k.htm" STYLE="-sec-extract: exhibit">June&nbsp;10,
                                                                  2020</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1549084/000110465920073400/tm2022617-1_8ka.htm" STYLE="-sec-extract: exhibit">June&nbsp;15,
                                                                  2020</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the description of our common stock contained in Exhibit 4.9 on Form 10-K as filed with the SEC
on <A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/ekso1231201910-k.htm" STYLE="-sec-extract: exhibit">February&nbsp;27, 2020</A>,
and any further amendment or report filed hereafter for the purpose of updating such description pursuant to Section 12(b) of the
Exchange Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incorporate
by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of
the Exchange Act after the date hereof but prior to the completion or termination of the offering, including all such documents
we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration
statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously
filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference
herein, modifies or supersedes that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As explained above
in &ldquo;Where You Can Find More Information,&rdquo; these incorporated documents (as well as other documents filed by us under
the Exchange Act) are available at the SEC and may be accessed online via the Internet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide without
charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that
person, a copy of any or all of the documents we are incorporating by reference into this prospectus, other than exhibits to those
documents unless such exhibits are specifically incorporated by reference into those documents. Such written requests should be
addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Ekso Bionics
Holdings,&nbsp;Inc.<BR>
1414 Harbour Way South, Suite&nbsp;1201<BR>
Richmond, California 94804<BR>
United States of America<BR>
Attn: Investor Relations<BR>
(510) 984-1761</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The documents incorporated
by reference may be accessed at our website at www.eksobionics.com. Except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement
of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1549084|000110465920073591|tm2022583d1_s3sp6img01.jpg" STYLE="height: 158px; width: 192px">&nbsp;<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<FONT STYLE="font-size: 14pt"><B>Ekso Bionics Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>873,852 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuable upon Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_016"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_017"></A>INFORMATION NOT REQUIRED
IN PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Unless otherwise
expressly stated or the context otherwise requires, references in this prospectus to (i) &ldquo;Ekso Bionics,&rdquo; &ldquo;the
Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; in this Part II refer to Ekso Bionics, Holdings, Inc.,
a Nevada corporation, and (ii) &ldquo;common stock&rdquo; refer to shares of the Company&rsquo;s common stock, $0.001 par value
per share.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is
an estimate (except for registration fees, which are actual) of the approximate amount of each type of fees and expenses listed
below that were paid or are payable by us in connection with the issuance and distribution of the shares of common stock to be
registered by this registration statement. None of the expenses listed below are to be borne by any of the selling stockholders
named in the prospectus that forms a part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; font-size: 10pt; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">784</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Printing and engraving expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">20,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">30,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,716</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">65,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Officers and Directors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevada Revised Statutes
(NRS) Sections&nbsp;78.7502 and 78.751 provide us with the power to indemnify any of our directors, officers, employees and agents.
The person entitled to indemnification must have conducted himself in good faith, and must reasonably believe that his conduct
was in, or not opposed to, our best interests. In a criminal action, the director, officer, employee or agent must not have had
reasonable cause to believe that his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under NRS Section&nbsp;78.751,
advances for expenses may be made by agreement if the director or officer affirms in writing that he has met the standards for
indemnification and will personally repay the expenses if it is determined that such officer or director did not meet those standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our by-laws state that
we shall indemnify every (i)&nbsp;present or former director, officer, employee or agent of us and (ii) any person who served at
our request as a director, officer, member, manager, partner, trustee, fiduciary, employee or agent of another corporation, limited
liability company, partnership, joint venture, trust, employee benefit plan or other enterprise (each an &ldquo;Indemnitee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our by-laws provide
that we shall indemnify an Indemnitee against expenses, including attorneys&rsquo; fees and disbursements, and costs (and in connection
with a proceeding other than a proceeding by or in the right of the Company, judgments, fines and amounts paid in settlement) actually
and reasonably incurred by such person in connection with any proceeding in which such Indemnitee was, is or is threatened to be
named as defendant or respondent, or in which he was or is a witness without being named a defendant or respondent, by reason,
in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined that
the Indemnitee (a)&nbsp;conducted himself in good faith and in a manner which such Indemnitee reasonably believed to be in or not
opposed to our best interests, or with respect to any criminal proceeding, had no reasonable cause to believe that his conduct
was unlawful or (b)&nbsp;is not liable pursuant to NRS Section&nbsp;78.138; provided, however, that in the event that an Indemnitee
is found liable to us, we will have no obligation to indemnify such Indemnitee unless, and only to the extent that the court in
which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses and costs as a court of competent jurisdiction
or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The termination of
any proceeding by judgment, order, settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself
determinative that the Indemnitee did not meet the requirements set forth in clauses (a)&nbsp;or (b)&nbsp;above. An Indemnitee
shall be deemed to have been found liable in respect of any claim, issue or matter only after the Indemnitee shall have been so
adjudged by a court of competent jurisdiction after exhaustion of all appeals therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our
by-laws, have entered into an Indemnification Agreement with each of our directors and executive officers pursuant to which we
are required to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law
and our governing documents. We believe that entering into these agreements helps us to attract and retain highly competent and
qualified persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been
advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See also the undertakings
set out in our response to Item 17 herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered
Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>June 2020 Warrants and H.C. Wainwright
Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2020, in
a registered direct offering (&ldquo;June 2020 Offering&rdquo;), the Company sold and issued an aggregate of 1,747,704 shares of
the common stock at an offering price of $4.5145 per share pursuant to the terms of a Securities Purchase Agreement, dated June
7, 2020, between the Company and certain accredited investors. Pursuant to the terms of the Securities Purchase Agreement, in a
concurrent private placement, the Company issued to the investors in the registered direct offering warrants to purchase up to
873,852 shares of the common stock in the aggregate issuable upon the exercise of warrants (the &ldquo;June 2020 Warrants&rdquo;).
The June 2020 Warrants have an exercise price of $5.18 per share, were exercisable as of the date of issuance and expire 5.5 years
following the date of issuance. On June 10, 2020, as compensation to H.C. Wainwright &amp; Co., LLC (&ldquo;H.C. Wainwright&rdquo;)
for its services in connection with the registered direct offering and concurrent private placement, the Company issued warrants
to purchase up to 122,339 shares of common stock issuable upon the exercise of warrants (the &ldquo;H.C. Wainwright Warrants&rdquo;)
in a private placement to H.C. Wainwright or its designees. The H.C. Wainwright Warrants have substantially the same terms as the
June 2020 Warrants, except that their exercise price is $5.6431 per share (equal to 125% of the registered direct offering price
per share) and are exercisable as of the date of issuance and expire 5 years following the effective date of the offering. <FONT STYLE="color: #212529; background-color: white">&nbsp;The
aggregate gross proceeds of the offerings is approximately $7.89 million, and expected proceeds to the Company, net of fees and
expenses, is approximately $7.07 million. The total aggregate fees and expenses was approximately $</FONT>729,100.78.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The June 2020 Warrants,
the H.C. Wainwright Warrants and the shares of common stock issuable upon exercise of the June 2020 Warrants and the H.C. Wainwright
Warrants&nbsp;were offered and sold without registration under the Securities Act, pursuant to the exemption provided in Section
4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder as transactions not involving a public offering and similar
exemptions under applicable state laws in reliance on the following facts: no general solicitation was used in other offer or sale
of such securities; the recipients of the securities had adequate access to information about the Company, through pre-existing
relationships or otherwise; and such securities were issued as restricted securities with restricted legends referring to the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
shares of common stock, but not the June 2020 Warrants, the H.C. Wainwright Warrants (the &ldquo;Private Placement Warrants&rdquo;)
or the shares of common stock underlying the Private Placement Warrants, were offered and sold pursuant to the Company&rsquo;s
Registration Statement on Form S-3 (No. 333-218517), including a base prospectus, which was previously filed with and declared
effective by the Securities and Exchange Commission on June 16, 2017, as supplemented by a prospectus supplement, dated June 7,
2020, filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Private Placement Warrants were offered
in concurrent private placements under Section 4(a)(2) of the Act, and Regulation D promulgated thereunder. The offer and sale
of the Private Placement Warrants and the shares of common stock underlying such warrants have not been registered under the Securities
Act, or applicable state securities laws. The Company is filing this prospectus with respect to the resale of the shares of common
stock underlying the June 2020 Warrants issuable upon exercise of such June 2020 Warrants. The H.C. Wainwright Warrants and the
underlying shares of common stock may not be offered or sold in the United States, except pursuant to an effective registration
statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I></I></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I>January 2019 Private
Placement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="color: #212529">The
Company entered into an agreement, dated January 30, 2019, by and among the Company and Zhejiang Youchuang Venture Capital Investment
Co., Ltd (&ldquo;ZYVC&rdquo;) and another partner (collectively, the &ldquo;JV Partners&rdquo;), as amended by the Amendment to
the Joint Venture Agreement, dated April&nbsp;30, 2019 (as amended, the &ldquo;JV Agreement&rdquo;) </FONT>to establish Exoskeleton
Intelligent Robotics Co. Limited (the &ldquo;China JV&rdquo;), a Chinese limited liability company designed to develop and serve
the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center in the Zhejiang
Province of China. In connection with the JV Agreement, the <FONT STYLE="color: #212529">JV Partners agreed to purchase the Company&rsquo;s
common stock in two tranches for</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;an aggregate of $10 million.
The JV Partners completed the first tranche of their purchase on</FONT> <FONT STYLE="color: #212529">January 30, 2019, in which
the Company sold 204,499 shares of its common stock for $5,000,000 at a purchase price of $24.45 per share. The second tranche
for the remaining </FONT>$5,000,000 <FONT STYLE="color: #212529">investment by the China JV or </FONT>ZYVC <FONT STYLE="color: #212529">or
its designees is contingent upon the China JV shipping the first batch of EksoGT, EksoVest and EksoZeroG Arm products to Ekso Bionics,
its affiliates or a third party. Pursuant to the JV Agreement, the investment is to be made within 30 business days of the China
JV delivery the first batch of finished EksoGT products to a buyer, through the purchase of shares of the Company's common stock
at a per share price equal to the volume weighted average of the closing price of the Company&rsquo;s common stock on the Nasdaq
Capital Market for the twenty (20) days prior to the date of issuance, provided that such purchase price per share shall be no
less than $19.50 and no more than $29.40. </FONT>The Company is relying on the exemption from the registration requirements of
the Securities Act, afforded by Regulation S promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the CFIUS investigation noted above under &ldquo;Risk Factors&mdash;Risks Related to Our Business,&rdquo; the Company
does not expect the second tranche of the investment to be completed, as it is very likely that our China JV will be terminated
and the shares acquired in connection with the China JV to be divested, including the first tranche of the investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><I>2017 Information
Agent Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On
September 13, 2017, in connection with a rights offering in August 2017, the Company entered into an amendment to the information
agent agreement between the Company and Katalyst Securities LLC (&ldquo;Katalyst&rdquo;) dated August 11, 2017 (the &ldquo;Information
Agent Agreement&rdquo;). Pursuant to the amendment, the Company agreed to issue to Katalyst, or its designee, warrants to purchase
an aggregate of 13,333 shares of the Company&rsquo;s common stock at an exercise price of $22.50 per share (the &ldquo;2017 Information
Agent Warrants&rdquo;). The 2017 Information Agent Warrants were immediately exercisable upon issuance and will expire three years
from the date of issuance, or September 13, 2020. The 2017 Information Agent Warrants were issued to Katalyst as compensation
for its services as information agent in connection with the Company&rsquo;s 2017 rights offering in lieu of the $200,000 in cash
compensation that would otherwise have been payable to Katalyst pursuant to the Information Agent Agreement. The Company issued
the 2017 Information Agent Warrants and will issue the shares of common stock issuable upon exercise of the 2017 Information Agent
Warrants in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index
immediately preceding the signature page hereto, which is incorporated in this Item 16 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;(a)&nbsp;&#9;The
undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration statement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the
maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration
statement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">To include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or any material change to such information in the
registration statement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><I>provided</I>, <I>however</I>,
that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-3 or Form F-3
and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under
the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide
</I>offering thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">That, for the purpose of determining liability under
the Securities Act of 1933 to any purchaser:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each prospectus filed pursuant to Rule 424(b) as part of the registration statement relating to
an offering, other than registration statements relying on Rule430B or other than prospectuses filed in reliance on Rule 430A,
shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrant&rsquo;s annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant
to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_018"></A>EXHIBIT INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following exhibits
are being filed with or incorporated by reference in this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Incorporated
    by Reference</B></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Exhibit<BR>
    No.</B></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><B>Description</B></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Form</B></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Filing Date</B></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Exhibit<BR>
    No.</B></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>Filed
    Herewith</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">2.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex2-1.htm" STYLE="-sec-extract: exhibit">Agreement
    and Plan of Merger and Reorganization, dated as of January&nbsp;15, 2014, by and among the Registrant, Acquisition Sub and
    Ekso Bionics,&nbsp;Inc.</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">2.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420415017256/v403902_ex3-1.htm" STYLE="-sec-extract: exhibit">Articles
    of Incorporation of the Registrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/19/15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000114420417065493/tv482098_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment of Certificate of Incorporation of Ekso Bionics Holdings,&nbsp;Inc.</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/27/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920037753/tm2013624d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to the Articles of Incorporation</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/24/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.4</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex3-4.htm" STYLE="-sec-extract: exhibit">By-Laws
    of the Registrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.4</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.5</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex3-3.htm" STYLE="-sec-extract: exhibit">Certificate
    of Merger of Ekso Bionics,&nbsp;Inc., with and into Acquisition Sub, filed January&nbsp;15, 2014.</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.6</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420415038664/v413845_ex4-4.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    specimen certificate</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">S-3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/23/15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.4</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.7</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420416099014/v438965_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Change of Ekso Bionics Holdings,&nbsp;Inc. effective May&nbsp;4, 2016</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/05/16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.8</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420416093290/v436201_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Designation of Series&nbsp;A Convertible Preferred Stock, filed on April&nbsp;4, 2016</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">04/07/16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">3.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.9</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420415072702/v427793_ex4-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    2015 Warrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/24/15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.10</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420419013306/tv515959_ex99-2.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    Amendment to 2015 Warrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/11/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">99.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.11</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000110465919076558/tm1928279d2_ex4-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    May&nbsp;2019 Warrant </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/24/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.12</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex4-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    December&nbsp;2019 Warrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/20/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.13</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex4-2.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    December&nbsp;2019 Placement Agent Warrant </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/20/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    June 2020 Warrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/10/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex4-2.htm" STYLE="-sec-extract: exhibit">Form
    of H.C. Wainwright Warrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/10/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000091957417005581/d7575979_ex10-2.htm" STYLE="-sec-extract: exhibit">Registration
    Rights Agreement</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">07/25/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920073591/tm2022583d1_ex4-20.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    Senior Trust Indenture</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;S-3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/16/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;4.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920073591/tm2022583d1_ex4-21.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    Subordinated Trust Indenture</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;S-3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/16/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;4.21</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920073591/tm2022583d1_ex4-20.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of
    Senior Debt Security</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;S-3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/16/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;4.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">4.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920073591/tm2022583d1_ex4-21.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Subordinated Debt Security</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;S-3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/16/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;4.21</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding-right: 3pt; padding-left: 3pt; text-align: center">5.1</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 3pt; padding-left: 3pt"><A HREF="tm2023834d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of Snell &amp; Wilmer L.L.P.</A></TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="color: blue"><U>Form of Registration Rights Agreement </U></FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.10</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114036119008051/nc10001374x1_def14a.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated 2014 Equity Incentive Plan</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">DEF 14A</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">04/20/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Appendix A</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-13.htm" STYLE="-sec-extract: exhibit">Form
    of Director Option Agreement under 2014 Equity Incentive Plan</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.4</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-14.htm" STYLE="-sec-extract: exhibit">Form
    of Employee Option Agreement under 2014 Equity Incentive Plan</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.5</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420417040909/v471408_ex10-46.htm" STYLE="-sec-extract: exhibit">Form
    of Employee Restricted Stock Unit Award under 2014 Equity Incentive Plan</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/07/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.46</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.6</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420417022835/v465227_def14a.htm" STYLE="-sec-extract: exhibit">2017
    Employee Stock Purchase Plan</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">DEF 14A</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">04/28/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Appendix A</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.7</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000114420418043722/tv500802_ex10-1.htm" STYLE="-sec-extract: exhibit">Jack
    Glenn Offer Letter dated July 24, 2018</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/13/18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.8</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420418043722/tv500802_ex10-2.htm" STYLE="-sec-extract: exhibit">Jack
    Glenn Employment Agreement effective August 13, 2018</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/13/18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.9</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420418057183/tv506199_ex10-1.htm" STYLE="-sec-extract: exhibit">Steven
    Sherman Offer Letter dated October 30, 2018</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">11/05/18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.10</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000162828018013896/ekso-093018xex103.htm" STYLE="-sec-extract: exhibit">Jack
    Peurach Employment Agreement dated August 7, 2018</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">11/07/18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.3</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.11</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit1011.htm" STYLE="-sec-extract: exhibit">Jason
    Jones Offer Letter dated September 19, 2018</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">02/27/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.11</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">10.12</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420419023745/tv520694_ex10-1.htm" STYLE="-sec-extract: exhibit">William
    Shaw Offer Letter dated April 2, 2019</A></TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">05/06/19</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.13</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-19.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated as of November 15, 2005, by and between The Regents of the University of California and Berkeley
    ExoTech, Inc., d/b/a Berkeley ExoWorks</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 7%">10.14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 49%"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414003452/v365778_ex10-20.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated as of July 14, 2008, by and between The Regents of the University of California and Berkeley ExoTech,
    Inc., d/b/a/ Berkeley Bionics and formerly d/b/a Berkeley ExoWorks (as amended by Amendment #1 to Exclusive License Agreement,
    dated as of May 20, 2009, by and between The Regents of the University of California and Berkeley Bionics)</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 8%">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 11%">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 8%">10.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414019450/v373064_ex10-25.htm" STYLE="-sec-extract: exhibit">Government
    Field Cross License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/31/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.25</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="color: blue"><U>Medical License Agreement dated as of July
    1, 2013 between Ekso Bionics and Lockheed Martin Corporation </U></FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/31/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.26</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414019450/v373064_ex10-27.htm" STYLE="-sec-extract: exhibit">Cross
    License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/31/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.27</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414029944/v377217_ex10-20.htm" STYLE="-sec-extract: exhibit">Form
    of Non-Employee Director Indemnification Agreement </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/13/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&dagger;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420414029944/v377217_ex10-21.htm" STYLE="-sec-extract: exhibit">Form
    of Executive Officer Indemnification Agreement </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/13/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.21</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420415072702/v427793_ex10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement dated December 23, 2015, between Ekso Bionics Holdings, Inc. and each purchaser thereto </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/24/15</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.21</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420416093290/v436201_ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Amendment to Securities Purchase Agreement&nbsp;</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">04/07/16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.22</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="color: blue"><U>Form of Amendment to Purchase Agreement</U></FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">03/11/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">99.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.23</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420418045684/tv501341_ex99-1.htm" STYLE="-sec-extract: exhibit">Form
    of Waiver of Subsequent Equity Sale Prohibition</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/21/18</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">99.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.24</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000091957417005581/d7575979_ex10-1.htm" STYLE="-sec-extract: exhibit">Purchase
    Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities
    II LLC</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">07/25/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.25</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000091957417005581/d7575979_ex10-2.htm" STYLE="-sec-extract: exhibit">Registration
    Rights Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities
    II LLC </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">07/25/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.26</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000110465919074976/tm1926727d1_ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Securities Purchase Agreement</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">12/20/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.27</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="color: blue"><U>Lease, dated November 29, 2011, between FPOC,
    LLC and Berkeley Bionics, Inc dba Ekso Bionics</U></FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/23/14</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.21</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.28</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit1028.htm" STYLE="-sec-extract: exhibit">First
    Amendment to Lease Agreement, dated March 28, 2012, between FPOC LLC and Berkeley Bionics, Inc. DBA Ekso Bionics, Inc.</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">02/27/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.28</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.29</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420416132829/v451418_ex10-38.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to Lease Agreement dated November 5, 2016, between FPOC, LLC and Ekso Bionics, Inc. </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">09/20/16</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.38</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.30</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420417001005/v456407_ex10-1.htm" STYLE="-sec-extract: exhibit">Loan
    and Security Agreement dated as of December 30, 2016 by and among the Registrant, Ekso Bionics, Inc. and Western Alliance
    Bank</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/06/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.31</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420417001005/v456407_ex10-2.htm" STYLE="-sec-extract: exhibit">Success
    Fee Agreement dated as of December 30, 2016 by and among the Registrant, Ekso Bionics, Inc. and Western Alliance Bank</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">01/06/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.32</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000114420417040909/v471408_ex10-48.htm" STYLE="-sec-extract: exhibit">First
    Amendment to Loan and Security Agreement, dated as August 3, 2017, by and among EKSO Bionics Holdings, Inc., EKSO Bionics,
    Inc. and Western Alliance Bank </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/07/17</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.48</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.33</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000154908420000016/ekso-3312020xex101.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to Loan and Security Agreement, dated April 29, 2020, by and between Western Alliance Bank, Ekso Bionics Holdings,
    Inc. and Ekso Bionics, Inc.</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">04/30/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 7%">10.34</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 49%"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908419000002/exhibit103612312018.htm" STYLE="-sec-extract: exhibit">Agreement
    for Consulting Services between Ekso Bionics Holdings, Inc and Angel Pond Capital, LLC, dated July 2017</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 8%">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 11%">02/28/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 8%">10.36</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.35</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908419000004/ekso-33119xex101.htm" STYLE="-sec-extract: exhibit">Equity
    Joint Venture Contract, dated January 30, 2019, by and among Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned
    subsidiary of Ekso Bionics Holdings, Inc., Zhejiang Youchuang Venture Capital Investment Co., Ltd. and Shaoxing City Keqiao
    District Paradise Silicon Intelligent Robot Industrial Investment Partnership </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/01/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.36</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908419000006/ekso-63019xex102.htm" STYLE="-sec-extract: exhibit">Amendment
    to the Joint Venture Contract of Exoskeleton Intelligent Robotics Co. Limited, dated April 30, 2019, by and among Ekso Bionics
    Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary of Ekso Bionics Holdings, Inc., Zhejiang Youchuang Venture Capital
    Investment Co., Ltd. and Shaoxing City Keqiao District Paradise Silicon Intelligent Robot Industrial Investment Partnership
    </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">08/01/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.37</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908419000004/ekso-33119xex102.htm" STYLE="-sec-extract: exhibit">Share
    Purchase Agreement, dated January 30, 2019, between Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary
    of Ekso Bionics Holdings, Inc. and the parties listed thereto </A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-Q</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">05/01/19</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.38</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1549084/000110465920072005/tm2022148d1_ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Securities Purchase Agreement</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">8-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">06/10/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.39</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">*</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit1037.htm" STYLE="-sec-extract: exhibit">Technology
    License Agreement, dated October 22, 2019, between Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary
    of Ekso Bionics Holdings, Inc. and Eksoskeleton Intelligent Robotics Co. Limited</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">02/27/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10.37</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">21.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1549084/000154908420000005/exhibit21112312019.htm" STYLE="-sec-extract: exhibit" STYLE="-sec-extract: exhibit">Subsidiaries of Registrant</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">10-K</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">02/27/20</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">21.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">23.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="tm2023834d1_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">23.2</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="tm2023834d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of
    Snell &amp; Wilmer L.L.P. (included in Exhibit&nbsp;5.1)</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">24.1</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><A HREF="#a_020">Power of Attorney (contained here on the signature page)</A></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&dagger;</TD><TD>Management contract, compensatory plan or arrangement.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">*</TD><TD STYLE="text-align: justify">Confidential Treatment portions of this exhibit have
been omitted as permitted by applicable regulations.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933,
the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Richmond, California, on July 2, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>EKSO BIONICS HOLDINGS,&nbsp;INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: July 2, 2020</TD>
    <TD>By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ &nbsp;Jack Peurach</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jack Peurach</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, the undersigned
officers and directors of Ekso Bionics Holdings,&nbsp;Inc., hereby severally constitute and appoint Jack Peurach and John F. Glenn,
and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution in each of them for her or him and in her or his name, place and stead, and in any
and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any
other registration statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b)&nbsp;under
the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority
to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents
and purposes as she or he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
or any of them or their or her or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>SIGNATURE</B>&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>TITLE</B>&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%; padding-right: 3pt; padding-left: 3pt; text-align: center"><B>DATE</B>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ Jack Peurach</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">President and Chief Executive Officer</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Jack Peurach</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">(<I>Principal Executive Officer</I>)&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ John F. Glenn</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Chief Financial Officer</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">John F. Glenn</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">(<I>Principal Financial Officer and Principal Accounting
    Officer</I>)</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/
    Steven Sherman</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">Director and
    Executive Chairman of the Board</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Steven Sherman</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ Marilyn Hamilton</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Director&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Marilyn Hamilton</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/Charles Li, Ph.D.</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Director&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Charles Li, Ph.D.</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ Thomas A. Schreck</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Director&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Thomas A. Schreck</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ Stanley Stern</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Director&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Stanley Stern</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center">/s/ Ted Wang, Ph.D.</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">Director&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; padding-right: 3pt; padding-left: 3pt; text-align: center">July 2, 2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">Ted Wang, Ph.D.</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "tm2023834d1_s1.htm", "description": "FORM S-1", "secsgml_size_bytes": 285872}]
{"company-data": {"conformed-name": "EKSO BIONICS HOLDINGS, INC.", "cik": "0001549084", "assigned-sic": "3569", "irs-number": "000000000", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-239679", "film-number": "201010844"}, "business-address": {"street1": "1414 HARBOUR WAY SOUTH", "street2": "SUITE 1201", "city": "RICHMOND", "state": "CA", "zip": "94804", "phone": "510-984-1761"}, "mail-address": {"street1": "1414 HARBOUR WAY SOUTH", "street2": "SUITE 1201", "city": "RICHMOND", "state": "CA", "zip": "94804"}, "former-company": {"former-conformed-name": "PN Med Group Inc", "date-changed": "20120503"}}
As filed with the Securities and Exchange
Commission on July 2, 2020
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Ekso Bionics Holdings, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
3841
99-0367049
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial Classification Code Number)
(I.R.S. Employer
Identification Number)
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(510) 984-1761
(Address, including zip code, and telephone
number, including
area code, of registrant's principal executive offices)
Jack Peurach
Chief Executive Officer
Ekso Bionics Holdings, Inc.
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(510) 984-1761
(Name, address, including zip code, and
telephone number, including
area code, of agent for service)
With Copies to:
Alfredo B. D. Silva, Esq.
Morrison & Foerster LLP
425 Market St.
San Francisco, CA 94105
(415) 268-7000
Approximate date of commencement of proposed
sale to the public:
As soon as practicable after the effective date hereof.
If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the
following box.
x
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated
filer
¨
Accelerated
filer
x
Non-accelerated filer
¨
Smaller reporting company
x
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
¨
CALCULATION
OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
Amount to be Registered
(1)
Proposed Maximum Offering Price Per Share
(3)
Proposed Maximum Aggregate Offering Price
Amount of Registration Fee
Common Stock, $0.001 par value per share
(2)
873,852
$6.91
$6,038,317.32
$783.77
(1)
Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include
such indeterminate number of additional shares of common stock, $0.001 par value per share ("Common Stock") as may
be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.
(2)
Represents the resale of shares of Common Stock issuable upon
the exercise of certain warrants issued in private placements described herein. Pursuant to Rule 416(a) under the Securities Act
of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover an indeterminate amount and
number of each identified class of the identified securities as may be issued upon conversion, exchange, exercise or settlement
of any other securities that provide for such conversion, exchange, exercise or settlement.
(3)
Estimated solely for the purpose of computing the amount of
the registration fee for the shares of common stock issuable upon exercise of warrants being registered in accordance with Rule
457(c) under the Securities Act based upon the average of the high and low prices for a share of the registrant's common
stock as reported on The Nasdaq Capital Market on June 25, 2020, which date is within five business days prior to the date of the
filing of this registration statement.
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The information in this
prospectus is not complete and may be changed. The selling stockholders may not sell these securities pursuant to this prospectus
until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not
permitted.
SUBJECT TO COMPLETION, DATED
JULY 2, 2020
PROSPECTUS
873,852 Shares of Common Stock
Issuable upon Exercise of Warrants
This prospectus relates
to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption "Selling Stockholders,"
of up to 873,852 shares of our common stock they may acquire upon the exercise of warrants issued on June 10, 2020, or the June
2020 Warrants. We issued the June 2020 Warrants to the selling stockholders in a private placement financing we completed in June 10,
2020. We are registering the applicable shares of our common stock to provide the selling stockholders with freely tradable securities.
The registration of the shares of our common stock covered by this prospectus does not necessarily mean that any shares of our
common stock will be sold by any of the selling stockholders, and we cannot predict when or in what amounts any of the selling
stockholders may sell any of our shares of common stock offered by this prospectus. The prices at which the selling stockholders
may sell the shares of our common stock will be determined by prevailing market prices or at prices that may be obtained in negotiated
transactions.
We are not selling any shares of our common stock under this
prospectus and will not receive any proceeds from any sale or disposition by the selling stockholders of the shares of our common
stock covered by this prospectus. However, we will receive proceeds in connection with the applicable exercise price of the June
2020 Warrants to purchase shares of our common stock, which, if exercised in cash with respect to all June 2020 Warrants, would
result in gross proceeds to us of approximately $4.5 million, but under certain circumstances such warrants may be exercised via
cashless exercise. In addition, we will pay all fees and expenses incident to the registration of the resale of shares of our common
stock under this prospectus. The selling stockholders from time to time may offer and sell the shares of our common stock held
by them directly or through one or more underwriters, broker-dealers or agents on terms to be determined at the time of sale, as
described in more detail in this prospectus under "Plan of Distribution." No shares of our common stock may be sold
without delivery of this prospectus describing the method and terms of the offering of such shares.
Our common stock is
listed and trades on The Nasdaq Capital Market under the symbol "EKSO." The last reported sale price of our common
stock on The Nasdaq Capital Market on June 30, 2020 was $8.40 per share.
Investing in our securities involves a high degree of risk.
Before making any investment decision, you should carefully review and consider all the information in this prospectus and the
documents incorporated by reference herein and therein, including the risks and uncertainties described under "Risk Factors"
beginning on page 6 of this prospectus and the risk factors incorporated by reference into this prospectus.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2020.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
1
FORWARD-LOOKING STATEMENTS
2
PROSPECTUS SUMMARY
4
THE OFFERING
5
RISK FACTORS
6
USE OF PROCEEDS
8
SELLING STOCKHOLDERS
9
PLAN OF DISTRIBUTION
11
DESCRIPTION OF COMMON STOCK TO BE REGISTERED
13
LEGAL MATTERS
14
EXPERTS
14
WHERE YOU CAN FIND MORE INFORMATION
14
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
15
ii
ABOUT THIS PROSPECTUS
This prospectus relates
to the resale by the selling stockholders identified in this prospectus under the caption "Selling Stockholders," from
time to time, of up to an aggregate of 873,852 shares of our common stock, par value $0.001 per share, issuable upon exercise of
certain common stock purchase warrants. As described below under "Prospectus Summary—Private Placement Offering,"
the shares of our common stock registered by this prospectus are issuable upon exercise of June 2020 Warrants to purchase up to
873,852 shares of our common stock for an exercise price of $5.18 per share issued on June 10, 2020, all of which are exercisable
by the selling stockholders. We will not receive any proceeds from the sale of shares of common stock offered hereby by the selling
stockholders. The registration statement containing this prospectus, including the exhibits to the registration statement, provides
additional information about us and the securities offered under this prospectus. The registration statement, including the exhibits,
can be read on the SEC's website or at the SEC offices mentioned under the heading "Where You Can Find More Information."
You should rely only
on the information contained or incorporated by reference in this prospectus. We are not selling any shares of our common stock
under this prospectus, and we have not authorized any other person to provide you with different information. If anyone provides
you with different information, you should not rely on it. This prospectus is not an offer to sell these securities and it is
not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume
that the information contained in this prospectus and the documents incorporated by reference herein and therein are accurate
only as of the date such information is presented. Neither the delivery of this prospectus nor any sale made in connection with
this prospectus, under any circumstances, create any implication that there has been no change in our affairs since the date of
this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.
This prospectus may
be supplemented from time to time to add, update or change information in this prospectus. Any statement contained in this prospectus
will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus
modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus is only
as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.
Unless otherwise expressly
stated or the context otherwise requires, references in this prospectus to (i) "Ekso Bionics," "the Company,"
 "we," "us," and "our" refer to Ekso Bionics Holdings, Inc., a Nevada corporation, and (ii) "common
stock" refer to shares of the Company's common stock, $0.001 par value per share. When we refer to "you,"
we mean the potential holders of our securities.
This prospectus and
the information incorporated by reference herein contain references to our trademarks and to trademarks belonging to other entities,
which are protected under applicable intellectual property laws. Solely for convenience, our trademarks and tradenames referred
to in this prospectus supplement appear without the ® and ™ symbol, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor
to these trademarks and tradenames. All trademarks, service marks and trade names included or incorporated by reference into this
prospectus are the property of their respective owners.
1
FORWARD-LOOKING STATEMENTS
This prospectus, as
well as the information incorporated by reference herein and therein, contain certain statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and
within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E
of the Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of historical facts,
included or incorporated in this prospectus regarding our strategy, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate,"
 "continue," "could," "due," "estimate," "expect," "goal,"
 "intend," "may," "objective," "plan," "predict," "potential,"
 "positioned," "seek," "should," "target," "will," "would"
and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms
or other comparable terminology, although not all forward-looking statements contain these identifying words.
Forward-looking statements
included or incorporated by reference in this prospectus include, for example, statements about:
•
our ability to obtain adequate financing to fund operations and to develop or enhance our technology;
•
the scope, scale and duration of the impact of outbreaks of a pandemic disease, such as COVID-19
(coronavirus);
•
our ability to obtain or maintain regulatory approval to market our medical devices;
•
our ability to complete clinical trials on a timely basis and that completed clinical trials will
be sufficient to support commercialization of our products;
•
the anticipated timing, cost and progress of the development and commercialization of new products
or services, and improvements to our existing products, and related impacts on our profitability and cash position;
•
our ability to effectively market and sell our products and expand our business, both in unit sales
and product diversification;
•
our ability to achieve broad customer adoption of our products and services;
•
our ability to achieve anticipated synergies and benefits of, and maintain our current and future
collaborations, joint ventures or partnerships;
•
existing or increased competition;
•
rapid changes in technological solutions available to our markets;
•
volatility with our business, including long and variable sales cycles, which could have a negative
impact on our results of operations for any given quarter or fiscal year;
•
changes in our domestic or international sales and operations;
•
our ability to obtain or maintain patent protection for our intellectual property;
•
the scope, validity and enforceability of our and third party intellectual property rights;
•
significant government regulation of medical devices and the healthcare industry;
•
our ability to unwind our role with the joint-venture in China in accordance with regulatory requirements;
•
outbreaks of a pandemic disease, such as COVID-19 (coronavirus);
2
•
our customers' ability to get third party reimbursement for our products and services associated
with them; our failure to implement our business plan or strategies;
•
our early termination of leases, difficulty filling vacancies or negotiating improved lease terms;
•
our ability to retain or attract key employees;
•
stock volatility or illiquidity;
•
our ability to maintain adequate internal controls over financial reporting;
•
the use of proceeds from, the timing of, and our ability to successfully complete this offering;
and
•
overall economic and market conditions.
These statements are
based on current expectations, assumptions, assessments, estimates, forecasts and projections about our business and the industry
in which we operate made by our management in light of its experience and its perception of historical trends, current conditions,
expected future developments and other factors our management believes to be appropriate. These forward-looking statements are
subject to a number of known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under "Risk Factors"
and elsewhere in this prospectus. and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as amended,
and our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2020 as such risk factors may be amended, updated or modified
periodically in our reports filed with the SEC, and the financial data and related notes and the reports incorporated by reference
in this prospectus, for further information on these and other risks affecting us.
Potential investors
are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak
only as of the date hereof and as of the dates indicated in these statements. Except as required by law, we assume no obligation
to update or revise these forward-looking statements for any reason, even if new information becomes available in the future, except
as required by law. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions
of future events. You should, however, review the factors and risks we describe in the reports we will file from time to time with
the Securities and Exchange Commission (the "SEC") after the date of this prospectus. See "Where You Can Find
More Information" and "Incorporation of Certain Documents by Reference."
3
PROSPECTUS SUMMARY
This summary highlights
certain information about us, this offering and the other information appearing elsewhere in this prospectus and in the documents
we incorporate by reference herein. This summary is not complete and does not contain all of the information that you should consider
before investing in our securities. To fully understand this offering and its consequences, you should read this entire prospectus
carefully, including the information set forth under the caption "Risk Factors" on page 6 in this prospectus and under
similar captions in the documents incorporated by reference herein, before making an investment decision.
Overview
We design, develop
and sell exoskeleton technology to augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets
and can be used both by able-bodied persons as well as by persons with physical disabilities. We have sold, rented or leased devices
that (i) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate, and
in some cases, to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow
industrial workers to perform difficult repetitive work for extended periods.
Our EksoVest is an
upper body exoskeleton that elevates and supports a worker's arms to assist them with tasks ranging from chest height to
overhead. In 2020, we are focusing on increasing sales of the EksoVest and the support arm, EksoZeroG, by pursuing alternative
channels, such as rental agreements with construction equipment and heavy tool providers and working with automotive and related
manufacturers to roll out our product(s) globally within their assembly operations. In addition, we believe that there is additional
mid-to-long-term potential in the industrial markets, and accordingly, we will continue our development efforts to expand our EksoWorks
product offerings.
We believe the commercial
opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic
and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements
have become ubiquitous in peoples' everyday lives. We believe that we have learned how to integrate these existing technologies
and wrap the result around a human being efficiently, elegantly and safely, supported by an industry-leading intellectual property
portfolio. We further believe that we can do so across a broad spectrum of applications, from persons with lower limb paralysis
to able-bodied users.
Additional details
of these programs and related strategic agreements are contained in our Annual Report on Form 10-K for the year ended December 31,
2019, as amended, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Private Placement Offering
On June 7, 2020, we entered into a securities purchase agreement
with certain purchasers, each of whom is an institutional and accredited investor, and on June 10, 2020, or the closing date, we
completed our offer and sale to certain accredited investors of (i) 1,747,704 shares of our common stock at a purchase price of
$4.5145 per share, which were sold in a registered direct offering, and (ii) June 2020 Warrants to purchase up to an aggregate
of 873,852 shares of our common stock, representing 50% of the shares of the common stock purchased in the registered direct offering,
which were sold in a concurrent private placement. The June 2020 Warrants had an initial exercise price of $5.18 per share (subject
to adjustment as set forth therein), were immediately exercisable and expire five and one-half years from the issue date, or on
December 10, 2025. All of the June 2020 Warrants contain certain ownership limitations that may restrict their exercise, as described
under the caption "Selling Stockholders" in this prospectus. In addition, all such warrants are exercisable on a cashless
basis if there is no effective registration statement registering, or no current prospectus available for, the resale of the shares
of common stock underlying the June 2020 Warrants by the holder. Pursuant to the stock purchase agreement, we agreed to file this
registration statement on Form S-1 with respect to the resale by the purchasers of the shares of common stock underlying the June
2020 Warrants issuable upon exercise of the June 2020 Warrants within 30 calendar days of the date of the securities purchase agreement,
or by July 7, 2020, and to use commercially reasonable efforts to cause such registration statement to become and remain effective.
Only the 873,852 shares issuable upon exercise of the June 2020 Warrants described in clause (ii) above are registered for resale
pursuant to this prospectus.
Corporate Information
Our corporate headquarters
are located at 1414 Harbour Way South, Suite 1201, Richmond, California. Our telephone number is (510) 984-1761, and our website
address is www.eksobionics.com. Our official Twitter account is @EksoBionics. The information on or accessible through our website
or our Twitter account does not constitute part of this prospectus supplement or the accompanying prospectus and should not be
relied upon in connection with making any investment in our securities.
On March 24,
2020, we effected a 1-for-15 reverse split of our common stock. As a result of the reverse stock split, every 15 shares of issued
and outstanding common stock were converted into one share of issued and outstanding common stock. We previously effected a 1-for-7
reverse stock split on May 4, 2016. Unless otherwise indicated, all references to share and per share amounts in this prospectus
supplement, reflect the reverse stock splits. Our common stock is listed on Nasdaq Capital Market under the symbol "EKSO."
4
THE OFFERING
Shares of common stock being offered by the selling stockholders:
Up to 873,852 shares of common stock issuable upon exercise
of June 2020 Warrants. See "Selling Stockholders" beginning on page 10 of this prospectus.
Use of proceeds:
All proceeds from the sale of the shares of common stock under this prospectus will be for the account of the selling stockholders. We will not receive any proceeds from the sale of our shares of common stock offered pursuant to this prospectus. Any net proceeds received by us from the exercise of the June 2020 Warrants will be used for general corporate purposes, which may include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. See the section entitled "Use of Proceeds" in this prospectus.
Nasdaq Capital Market symbol:
EKSO
Listing:
Our common stock is listed and trades on The Nasdaq Capital Market. There is no established trading market for the June 2020 Warrants and we do not intend to list such warrants on any exchange or other trading or quotation system.
Dividend policy:
We do not anticipate paying any cash dividends on our common stock in the foreseeable future.
Risk factors:
Investing in our securities involves a high degree of risk.
Before you decide to invest in our common stock, you should carefully read this prospectus in its entirety and carefully consider
the risks and uncertainties described in "Risk Factors" beginning on page 6 of this prospectus and in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2019, as amended, and our Quarterly Reports on Form 10-Q for the quarter ended
March 31, 2020, as such risk factors may be amended, updated or modified periodically in our reports filed with the Securities
and Exchange Commission (the "SEC"), and the financial data and related notes and the reports incorporated by reference
herein and therein.
5
RISK FACTORS
Investing in shares
of our common stock involves significant risks. You should carefully consider the specific risks described below, as well as the
other information contained in this prospectus and the other documents incorporated by reference, before making an investment decision.
Please see the risk factors under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as amended,
and as revised or supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our most recent Annual
Report on Form 10-K, each of which are on file with the SEC and are incorporated by reference in this prospectus. Before making
an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference
in this prospectus. See the sections of this prospectus entitled "Where You Can Find More Information" and "Incorporation
of Certain Documents By Reference." Any of the risks we describe below or in the information incorporated herein by reference
in this prospectus could cause our business, financial condition or operating results to suffer. The market price of our common
stock could decline if one or more of these risks and uncertainties develop into actual events. You could lose all or part of your
investment.
Risks Related to this
Offering
You may experience future dilution as a result of future
equity offerings.
In order to raise additional capital, we
may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share
that is equal to or greater than the price per share that you pay for the shares offered by this prospectus, and investors purchasing
shares or other securities in future offerings could have rights superior to existing stockholders. A significant portion of our
total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop
significantly, even if our business is doing well.
Sales of a significant number of shares of our common
stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.
Sales of a substantial number of shares
of our common stock, or other equity-related securities in the public markets, or the perception that such sales could occur, could
depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.
We have registered for sale shares of common stock issuable from time to time upon the exercise of certain outstanding warrants
to purchase common stock, including: (i) warrants to purchase 106,896 shares of common stock with an exercise price of $41.25
per share, expiring on December 23, 2020 (the "2015 Warrants"), (ii) warrants to purchase 444,444 shares
of common stock with an exercise price of $3.52 per share, expiring on May 24, 2024 (the "May 2019 Warrants"),
(iii) warrants to purchase 51,836 shares of common stock with an exercise price of $8.44, expiring on December 18, 2025
(the "December 2019 Placement Agent Warrants") and (iv) warrants to purchase 555,763 shares of common stock
with an exercise price of $8.10, expiring on June 21, 2025 (the "December 2019 Warrants" and, together with
the 2015 Warrants, the May 2019 Warrants, and the December 2019 Placement Agent Warrants, the "Registered Warrants").
Assuming that all the Registered Warrants are exercised in full, based upon the shares outstanding as of March 31, 2020, we
will have outstanding an aggregate of 7,002,381 shares of common stock, assuming no exercise of outstanding stock options, no settlement
of restricted stock units, no exercises of any other warrants to purchase our common stock and no other sales or issuances of our
common stock. A substantial majority of the outstanding shares of our common stock are, and all of the shares sold upon exercise
of the Registered Warrants will be, freely tradable without restriction or further registration under the Securities Act, unless
these shares are owned or purchased by "affiliates" as that term is defined in Rule 144 under the Securities Act.
In addition, we have also registered all
of the shares of common stock that we may issue pursuant to the exercise of outstanding stock options and settlement of restricted
stock units granted under our Amended and Restated 2014 Equity Incentive Plan, or 2014 Incentive Plan, and all of the shares of
common stock that we may issue under our Amended and Restated 2014 Equity Incentive Plan Employee Stock Purchase Plan, or ESPP.
As of March 31, 2020, 349,215 shares of our common stock were reserved for issuance of future awards under our 2014 Incentive
Plan and 500,000 shares of common stock were reserved for issuance under our ESPP. As a result, these shares can be freely sold
in the public market upon issuance, subject to restrictions related to affiliate sales under the securities laws. Additionally,
as of March 31, 2020, 13,333 shares of common stock were issuable upon the exercise of outstanding warrants other than the
Registered Warrants at an exercise price of $22.50 per share. These shares will only be freely tradable after issuance if registered
in the future under the Securities Act or in reliance on any available exemptions from the registration requirement of the Securities
Act.
Further, the May 2019 Warrants contain
price-based anti-dilution adjustment provisions. Future anti-dilution adjustments to such warrants may result in substantial additional
dilution to existing stockholders and may depress the market price of our common stock. The issuance of the shares of common stock
underlying these warrants, or perception that issuance may occur, will have a dilutive impact on other stockholders and could have
a material negative effect on the market price of our common stock.
6
We do not currently intend to pay dividends on our common
stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.
At the present time, we intend to use available
funds to finance our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors
(subject to any contractual restrictive covenants, such those in our loan agreement with the Western Alliance Bank), we have no
current intention of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all,
only from potential increases in the price of our common stock.
Risks Related to our Business
The recently announced Committee on Foreign Investment
in the United States determination requires us to terminate our China JV, which will adversely impact our ability to expand operations
globally and in particular, in China.
On January 30, 2019, we and our wholly-owned
subsidiary, Ekso Bionics, Inc. ("Ekso US"), entered into an agreement with Zhejiang Youchuang Venture Capital Investment
Co., Ltd ("ZYVC") and another partner (collectively, the "JV Partners"), as amended by the Amendment to
the Joint Venture Agreement, dated April 30, 2019 (as amended, the "JV Agreement") to establish Exoskeleton Intelligent
Robotics Co. Limited (the "China JV"), a Chinese limited liability company designed to develop and serve the exoskeleton
market in China and other Asian markets and to create a global exoskeleton manufacturing center in the Zhejiang Province of China.
In connection with the China JV, the JV Partners and their affiliates agreed to purchase an aggregate of 204,499 shares of our
common stock at a price per share equal to $24.45, for aggregate proceeds to us of $5.0 million.
As previously disclosed, following U.S. governmental
inquiries regarding the China JV, the Company and the China JV formally submitted a joint voluntary notice to Committee on Foreign
Investment in the United States ("CFIUS") in December 2019 to review the transaction. CFIUS subsequently inquired
about our legacy work for the U.S. government as well as technology transfers and other aspects of the China JV and, in February 2020,
imposed interim measures to mitigate identified concerns pending completion of its investigation. These measures temporarily suspended
the Company's contributions to the China JV and other integration activities for the China JV.
On May 19, 2020, we received notice
from CFIUS in connection with its review of the Company's and the JV Partners' investment the China JV. The notice
states that CFIUS's prior national security concerns regarding the JV could not be mitigated and, in connection with its
determination, CFIUS presented the Company and the JV Partners with a draft National Security Agreement ("NSA"), which
will, among other things, require the termination of the Company's role with the China JV. The Company intends to work cooperatively
with the JV Partners and CFIUS to finalize the terms of the NSA. In the event the parties cannot agree on the NSA's terms,
CFIUS will refer the matter to the President of the United States, who very likely will order the termination of the China JV and
the divestment of the shares acquired in connection with the China JV, per the President's authority under the Defense Production
Act.
Although the termination of the China JV
is not expected to have a material impact on the Company's operations during the remainder of 2020, if the Company is unable
to efficiently identify and partner with other global manufacturing sources and Asia-based distributors, we may not be able to
reduce the cost of manufacturing our products or increase sales in Asia in a cost-effective manner, which could have a material
adverse effect on our financial results in future periods.
7
USE OF PROCEEDS
We will not receive
any proceeds from the sale of the shares of our common stock issuable upon exercise of the June 2020 Warrants to purchase shares
of our common stock by the selling stockholders from time to time pursuant to this prospectus. The proceeds from the offering are
solely for the account of the selling stockholders. See "Selling Stockholders."
We will, however,
receive proceeds from any cash exercise of the June 2020 Warrants. If the June 2020 Warrants were exercised in cash with respect
to all of the 873,852 shares of common stock subject thereto, we would receive gross proceeds of approximately $4.5 million. We
cannot predict when or if the June 2020 Warrants will be exercised, and it is possible that such warrants may expire and never
be exercised.
Any
net proceeds received by us from the exercise of the June 2020 Warrants will be used for general corporate purposes, which may
include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities
expansion, and to meet working capital needs. We expect from time to time to evaluate the acquisition of businesses, products and
technologies for which a portion of the net proceeds may be used.
This
represents our best estimate of the manner in which we will use any net proceeds we receive from the exercise of the June 2020
Warrants based on the status of our business, but we have not reserved or allocated amounts for specific purposes and we cannot
specify with certainty how or when we would use any net proceeds. The amounts and timing of our actual expenditures may vary significantly
depending on numerous factors, including the amount and timing of the proceeds received from the exercise of the June 2020 Warrants
and progress with the achievement of our corporate goals. Expenditures will also depend upon the establishment and maintenance
of manufacturing and supply chains, the availability of additional financing and other factors.
We
will have broad discretion in the application of any net proceeds we receive, and we could use any such proceeds for purposes other
than those currently contemplated. Pending the use of the net proceeds from this offering as described above, we may invest the
net proceeds in a variety of capital preservation investments, including short- and intermediate-term, interest-bearing obligations,
investment-grade instruments or U.S. government securities. Investors will be relying on the judgment of our management regarding
the application of the proceeds of any sale of shares of our common stock.
8
SELLING STOCKHOLDERS
This prospectus covers
an aggregate of up to 873,852 shares of our common stock that may be sold or otherwise disposed of by the selling stockholders
identified herein. Such shares are issuable to the selling stockholders upon the exercise of June 2020 Warrants we issued and
sold to the selling stockholders in a private placement transaction, as described above under "Prospectus Summary—Private
Placement Offering."
When we refer to the
selling stockholders in this prospectus, we mean those persons listed in the table below, as well as the permitted transferees,
pledgees, donees, assignees, successors and others who later come to hold any of the selling stockholders' interests other
than through a public sale.
The selling stockholders
may from time to time offer and sell pursuant to this prospectus any or all of the shares of common stock set forth in the following
table. There is no requirement for the selling stockholders to sell their shares, and we do not know when, or if, or in what amount
the selling stockholders may offer the shares of common stock for sale pursuant to this prospectus.
The selling stockholders
identified below may have sold, transferred or otherwise disposed of some or all of their shares since the date on which the information
in the following table is presented in transactions exempt from or not subject to the registration requirements of the Securities
Act. Information concerning the selling stockholders may change from time to time and, if necessary, we will supplement this prospectus
accordingly. We are unable to confirm whether the selling stockholders will in fact sell any or all of their shares of common stock.
To our knowledge and
except as noted below, none of the selling stockholders has, or within the past three years has had, any material relationships
with us or any of our affiliates.
Name of Selling Stockholder
(1)
Number of Shares of Common Stock Owned Prior to Offering
(2)
Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus
(3)
Number of Shares Owned After Offering
Percent of Shares of Common Stock Owned After Offering (%)
(4)
Anson Investments Master Fund LP
(5)
499,109
276,886
222,223
2.56
Armistice Capital Master Fund Ltd.
(6)
653,414
320,080
333,334
3.84
Intracostal Capital, LLC
(7)
276,886
276,886
––
––
*
Less than 1%
(1)
The information in this table and the related notes is based upon information supplied by the selling
stockholders, including reports and amendments thereto filed with the SEC on Schedules 13G.
(2)
Represents the total number of shares of our common stock owned by or issuable to the relevant
selling stockholder as of the date of this prospectus, without regard to ownership limitations set forth in the applicable agreements
or other documents relating to such shares and without regard to initial exercise or conversion dates of exercisable or convertible
securities owned by such selling stockholder, including (i) all of the shares offered by this prospectus, and (ii) to our knowledge,
all other securities held by such selling stockholder as of the date of this prospectus.
(3)
Assumes that none of the June 2020 Warrants that are exercisable for the shares of our common stock
offered by this prospectus have been sold or otherwise transferred prior to the date of this prospectus in transactions exempt
from the registration requirements of the Securities Act. All June 2020 Warrants contain certain beneficial ownership limitations,
which provide that a holder of the June 2020 Warrants will not have the right to exercise any portion of its June 2020 Warrants
if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock
outstanding immediately after giving effect to such exercise, provided that upon at least 61 days prior notice to us, a holder
may increase or decrease such limitation up to a maximum of 9.99% of the number of shares of common stock outstanding. However,
the number of shares of common stock reflected in this column as owned by each selling stockholder does not take into account such
beneficial ownership limitations.
9
(4)
The percentage of beneficial ownership is based on 7,811,103
shares outstanding as of July 1, 2020, plus the 873,852 shares issuable upon exercise of the June 2020 Warrants, assuming full exercise of such warrants. The number of shares of common stock reflected in this column as owned by each selling stockholder
assumes that (a) all shares to be sold in this offering are sold, and (b) after the date of this prospectus and prior to completion
of this offering, none of the selling stockholders (i) acquires additional shares of our common stock or other securities
or (ii) sells or otherwise disposes of shares of our common stock or other securities held by such selling stockholders as
of the date hereof and not offered hereby.
(5)
Anson Advisors Inc. and Anson Funds Management LP are the co-investment advisers of Anson Investments
Master Fund LP, and, in such capacity, may be deemed to have voting and dispositive power over the securities held for the account
of Anson Investments Master Fund LP. Bruce Winson is the managing member of Anson Management GP LLC, which is the general partner
of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Messrs. Winson, Kassam and Nathoo
each disclaim beneficial ownership of this common stock, except to the extent of their pecuniary interest therein. The principal
business address of Anson Investments Master Fund LP is Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, George
Town, Grand Cayman KY1-9008, Cayman Islands.
(6)
Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. and Steven
Boyd is the managing member of Armistice Capital, LLC, and, in such capacity, Armistice Capital, LLC and Steven Boyd may be deemed
to have voting and dispositive power over the securities held for the account of Armistice Capital Master Fund Ltd. Armistice Capital,
LLC and Steven Boyd disclaim beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest
therein. The address for Armistice Capital, LLC is 501 Madison Avenue, 7th Floor, New York, NY 10022.
(7)
Mitchell P. Kopin and Daniel B. Asher, are each managers of Intracoastal Capital LLC, and, in such
capacity, may be deemed to have voting and dispositive power over the securities held for the account of Intracoastal Capital LLC.
The address for Intracoastal Capital LLC is 2211A Lakeside Drive, Bannockburn, IL 60015.
10
PLAN OF DISTRIBUTION
Each selling stockholder
of the shares of common stock and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their shares of our common stock included in the registration statement of which this prospectus is a part, on The Nasdaq
Capital Market or any other stock exchange, market or trading facility on which the shares of common stock are traded or in private
transactions. These sales may be in one or more transactions at fixed prices, at prevailing market prices at the time of the sale,
at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may sell such shares directly
or through one or more underwriters, broker-dealers or agents. If the shares of our common stock are sold through underwriters
or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent's commissions.
A selling stockholder
may use any one or more of the following methods when selling securities:
•
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchases;
•
block trades in which the broker-dealer will attempt to sell the shares as agent but may position
and resell a portion of the block as principal to facilitate the transaction;
•
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
•
an exchange distribution in accordance with the rules of the applicable exchange;
•
privately negotiated transactions;
•
settlement of short sales;
•
in transactions through broker-dealers that agree with the selling stockholder to sell a specified
number of such shares at a stipulated price per share;
•
through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;
•
a combination of any such methods of sale; or
•
any other method permitted pursuant to applicable law.
The selling stockholders
may also resell all or a portion of the shares of common stock under Rule 144 under the Securities Act or any other exemption from
registration, if available, rather than under this prospectus.
Broker-dealers engaged
by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of our common stock, from
the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121.
In connection with
the sale of the shares of common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course
of hedging the positions they assume. The selling stockholders may also sell common stock short and deliver these shares of common
stock to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these shares
of common stock. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial
institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institutions
of shares of common stock offered by this prospectus, which shares of common stock such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The selling stockholders
may pledge or grant a security interest in some or all of the June 2020 Warrants or shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock from time to time pursuant to this prospectus or other applicable provision of the Securities Act, amending, if necessary,
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under
this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which
case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.
11
The selling stockholders
and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be "underwriters"
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the shares of common stock and that there is no underwriter
or coordinating broker acting in connection with the proposed sale of the shares of common stock offered hereby by the selling
stockholders.
We will pay all fees and expenses of the registration of the
shares of common stock, estimated to be approximately $65,000 in total, including, without limitation, SEC filing fees and expenses
of compliance with state securities or "blue sky" laws; provided, however, that a selling stockholder will pay all
underwriting discounts and selling commissions, if any.
The common stock offered
hereby will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for
sale in such state or an exemption from registration or qualification is available and is complied with.
Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the shares of common stock offered hereby may
not simultaneously engage in market making activities with respect to the shares of common stock for the applicable restricted
period, as defined by Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be
subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may
limit the timing of purchases and sales of the shares of common stock by the selling stockholders or any other person.
Once sold under the
registration statement, of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands
of persons other than our affiliates.
12
DESCRIPTION OF COMMON STOCK TO BE REGISTERED
We are authorized to issue 141,428,571 shares
of common stock, par value $0.001 per share. On July 1, 2020, we had 7,811,103 shares of common stock outstanding and approximately
202 stockholders of record. In this offering, the selling stockholders are offering up to 873,852 shares of our common stock they
 may acquire upon the exercise of June 2020 Warrants.
The following summary of certain provisions
of our common stock does not purport to be complete. You should refer to our articles of incorporation and our bylaws, both of
which are included as exhibits to the registration statement of which this prospectus is a part. The summary below is also qualified
by provisions of applicable law.
General
Dividends.
The holders of outstanding
shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends
of such times and in such amounts as the board from time to time may determine.
Voting
. Holders of common stock are
entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the
election of directors then standing for election.
Pre-emptive Rights, Redemption, Conversion
and Sinking Fund Provisions
. The common stock is not entitled to pre-emptive rights and is not subject to conversion, redemption
or sinking fund provisions.
Liquidation Rights.
Upon liquidation,
dissolution or winding up of our Company, the assets legally available for distribution to stockholders are distributable ratably
among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims
of creditors. Each outstanding share of common stock is duly and validly issued, fully paid and non-assessable.
Transfers
. There are no restrictions
on the transfer of our common stock except such restrictions as may be imposed by applicable securities laws.
Description of Outstanding June 2020 Warrants to Purchase
Shares of Common Stock pursuant to which the Offered Shares of Common Stock May Be Issued
The following description
summarizes the material terms and provisions of the June 2020 Warrants.  As of July 1, 2020, there were 873,852
June 2020 Warrants outstanding to purchase shares of common stock. The June 2020 Warrants were immediately exercisable on June
10, 2020 and remain exercisable until the 5.5-year anniversary of their date of issuance, but not thereafter. The June 2020
Warrants are exercisable at an exercise price of $5.18 per share, which exercise price in each case, along with the number of shares
of common stock issuable upon the exercise of such warrants, will be subject to adjustment for stock splits, reverse splits, stock
dividends, and similar capital transactions as described in the June 2020 Warrants. A holder of June 2020 Warrants will have the
right to exercise such warrants on a "cashless" basis if at the time of exercise, there is no effective registration
statement registering, or no current prospectus available for, the resale of the shares of common stock underlying the June 2020
Warrants by the holder. A holder of June 2020 Warrants will not have the right to exercise any portion of its June 2020 Warrants
if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the investor's election),
of the number of our shares of our common stock outstanding immediately after giving effect to such exercise; provided, however,
that upon at least 61 days prior notice to us, a holder may increase or decrease such limitation up to a maximum of 9.99% of the
number of shares of common stock outstanding.
Holders of the June
2020 Warrants have the right to participate in any rights offering, dividend or distribution of assets together with the holders
of our common stock on an as-exercised basis.
Transfer Agent and Registrar
The transfer agent
and registrar for our shares of common stock is VStock Transfer, LLC. Its address is 18 Lafayette Place, Woodmere, New York 11598
and its telephone number is (212) 828-8436.
Trading Market
Our shares of common
stock are listed on The Nasdaq Capital Market under the symbol "EKSO."
13
LEGAL MATTERS
The validity of the
common stock offered by this prospectus will be passed upon for us by Snell & Wilmer L.L.P., San Francisco, California.
EXPERTS
OUM & Co.
LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form
10-K for the year ended December 31, 2019, as set forth in their report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on OUM &
Co. LLP's report, given on their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement under the
Securities Act that registers the securities offered hereby. The registration statement, including the exhibits and schedules attached
thereto and the information incorporated by reference therein, contains additional relevant information about the securities and
our company, which we are allowed to omit from this prospectus pursuant to the rules and regulations of the SEC. In addition, we
file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to
the public over the Internet at the SEC's website at www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish
to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These
filings will be available free of charge as soon as reasonably practicable after we electronically file such material with, or
furnish it to, the SEC.
We maintain a web site
at www.eksobionics.com. Information contained on our website is neither incorporated by reference into this prospectus nor a part
hereof or any other document we file with or furnish to the SEC.
14
INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE
The SEC allows us to
incorporate by reference into this prospectus certain information contained in other documents and reports that we file with it,
which means that we can disclose important information to you by referring you to such documents and reports. The information incorporated
by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically
update and supersede information contained in this prospectus. We incorporate by reference the documents listed below that we have
previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed "filed" pursuant to the General
Instructions of Form 8-K):
•
our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the
SEC on
February 27, 2020
, and amended on Form 10-K/A filed with the SEC on
April 28, 2020
;
•
our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, filed with the SEC
on
April 30, 2020
;
•
our Current Reports on Form 8-K, filed with the SEC on
January
                                                                  10, 2020
(Item 8.01 only),
January 22,
                                                                  2020
,
March 18,
                                                                  2020
,
March 24,
                                                                  2020
,
April 1,
                                                                  2020
,
April 24,
                                                                  2020
,
May 15,
                                                                  2020
,
June 10,
                                                                  2020
, and
June 15,
                                                                  2020
; and
•
the description of our common stock contained in Exhibit 4.9 on Form 10-K as filed with the SEC
on
February 27, 2020
,
and any further amendment or report filed hereafter for the purpose of updating such description pursuant to Section 12(b) of the
Exchange Act.
We also incorporate
by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of
the Exchange Act after the date hereof but prior to the completion or termination of the offering, including all such documents
we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration
statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously
filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference
herein, modifies or supersedes that statement.
As explained above
in "Where You Can Find More Information," these incorporated documents (as well as other documents filed by us under
the Exchange Act) are available at the SEC and may be accessed online via the Internet.
We will provide without
charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that
person, a copy of any or all of the documents we are incorporating by reference into this prospectus, other than exhibits to those
documents unless such exhibits are specifically incorporated by reference into those documents. Such written requests should be
addressed to:
Ekso Bionics
Holdings, Inc.
1414 Harbour Way South, Suite 1201
Richmond, California 94804
United States of America
Attn: Investor Relations
(510) 984-1761
The documents incorporated
by reference may be accessed at our website at www.eksobionics.com. Except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement
of which it forms a part.
15
Ekso Bionics Holdings, Inc.
873,852 Shares of Common Stock
Issuable upon Exercise of Warrants
PROSPECTUS
, 2020
16
PART II
INFORMATION NOT REQUIRED
IN PROSPECTUS
Unless otherwise
expressly stated or the context otherwise requires, references in this prospectus to (i) "Ekso Bionics," "the
Company," "we," "us," and "our" in this Part II refer to Ekso Bionics, Holdings, Inc.,
a Nevada corporation, and (ii) "common stock" refer to shares of the Company's common stock, $0.001 par value
per share.
Item 13. Other Expenses of Issuance and Distribution.
Set forth below is
an estimate (except for registration fees, which are actual) of the approximate amount of each type of fees and expenses listed
below that were paid or are payable by us in connection with the issuance and distribution of the shares of common stock to be
registered by this registration statement. None of the expenses listed below are to be borne by any of the selling stockholders
named in the prospectus that forms a part of this registration statement.
SEC registration fee
$
784
Printing and engraving expenses
$
12,500
Accounting fees and expenses
$
20,000
Legal fees and expenses
$
30,000
Miscellaneous
$
1,716
Total
$
65,000
Item 14. Indemnification of Officers and Directors.
Nevada Revised Statutes
(NRS) Sections 78.7502 and 78.751 provide us with the power to indemnify any of our directors, officers, employees and agents.
The person entitled to indemnification must have conducted himself in good faith, and must reasonably believe that his conduct
was in, or not opposed to, our best interests. In a criminal action, the director, officer, employee or agent must not have had
reasonable cause to believe that his conduct was unlawful.
Under NRS Section 78.751,
advances for expenses may be made by agreement if the director or officer affirms in writing that he has met the standards for
indemnification and will personally repay the expenses if it is determined that such officer or director did not meet those standards.
Our by-laws state that
we shall indemnify every (i) present or former director, officer, employee or agent of us and (ii) any person who served at
our request as a director, officer, member, manager, partner, trustee, fiduciary, employee or agent of another corporation, limited
liability company, partnership, joint venture, trust, employee benefit plan or other enterprise (each an "Indemnitee").
Our by-laws provide
that we shall indemnify an Indemnitee against expenses, including attorneys' fees and disbursements, and costs (and in connection
with a proceeding other than a proceeding by or in the right of the Company, judgments, fines and amounts paid in settlement) actually
and reasonably incurred by such person in connection with any proceeding in which such Indemnitee was, is or is threatened to be
named as defendant or respondent, or in which he was or is a witness without being named a defendant or respondent, by reason,
in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined that
the Indemnitee (a) conducted himself in good faith and in a manner which such Indemnitee reasonably believed to be in or not
opposed to our best interests, or with respect to any criminal proceeding, had no reasonable cause to believe that his conduct
was unlawful or (b) is not liable pursuant to NRS Section 78.138; provided, however, that in the event that an Indemnitee
is found liable to us, we will have no obligation to indemnify such Indemnitee unless, and only to the extent that the court in
which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses and costs as a court of competent jurisdiction
or such other court shall deem proper.
The termination of
any proceeding by judgment, order, settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself
determinative that the Indemnitee did not meet the requirements set forth in clauses (a) or (b) above. An Indemnitee
shall be deemed to have been found liable in respect of any claim, issue or matter only after the Indemnitee shall have been so
adjudged by a court of competent jurisdiction after exhaustion of all appeals therefrom.
II-
1
In addition to our
by-laws, have entered into an Indemnification Agreement with each of our directors and executive officers pursuant to which we
are required to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law
and our governing documents. We believe that entering into these agreements helps us to attract and retain highly competent and
qualified persons.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been
advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.
See also the undertakings
set out in our response to Item 17 herein.
Item 15. Recent Sales of Unregistered
Securities.
June 2020 Warrants and H.C. Wainwright
Warrants
On June 10, 2020, in
a registered direct offering ("June 2020 Offering"), the Company sold and issued an aggregate of 1,747,704 shares of
the common stock at an offering price of $4.5145 per share pursuant to the terms of a Securities Purchase Agreement, dated June
7, 2020, between the Company and certain accredited investors. Pursuant to the terms of the Securities Purchase Agreement, in a
concurrent private placement, the Company issued to the investors in the registered direct offering warrants to purchase up to
873,852 shares of the common stock in the aggregate issuable upon the exercise of warrants (the "June 2020 Warrants").
The June 2020 Warrants have an exercise price of $5.18 per share, were exercisable as of the date of issuance and expire 5.5 years
following the date of issuance. On June 10, 2020, as compensation to H.C. Wainwright & Co., LLC ("H.C. Wainwright")
for its services in connection with the registered direct offering and concurrent private placement, the Company issued warrants
to purchase up to 122,339 shares of common stock issuable upon the exercise of warrants (the "H.C. Wainwright Warrants")
in a private placement to H.C. Wainwright or its designees. The H.C. Wainwright Warrants have substantially the same terms as the
June 2020 Warrants, except that their exercise price is $5.6431 per share (equal to 125% of the registered direct offering price
per share) and are exercisable as of the date of issuance and expire 5 years following the effective date of the offering.
The
aggregate gross proceeds of the offerings is approximately $7.89 million, and expected proceeds to the Company, net of fees and
expenses, is approximately $7.07 million. The total aggregate fees and expenses was approximately $
729,100.78.
The June 2020 Warrants,
the H.C. Wainwright Warrants and the shares of common stock issuable upon exercise of the June 2020 Warrants and the H.C. Wainwright
Warrants were offered and sold without registration under the Securities Act, pursuant to the exemption provided in Section
4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder as transactions not involving a public offering and similar
exemptions under applicable state laws in reliance on the following facts: no general solicitation was used in other offer or sale
of such securities; the recipients of the securities had adequate access to information about the Company, through pre-existing
relationships or otherwise; and such securities were issued as restricted securities with restricted legends referring to the Securities
Act.
The
shares of common stock, but not the June 2020 Warrants, the H.C. Wainwright Warrants (the "Private Placement Warrants")
or the shares of common stock underlying the Private Placement Warrants, were offered and sold pursuant to the Company's
Registration Statement on Form S-3 (No. 333-218517), including a base prospectus, which was previously filed with and declared
effective by the Securities and Exchange Commission on June 16, 2017, as supplemented by a prospectus supplement, dated June 7,
2020, filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act.
The Private Placement Warrants were offered
in concurrent private placements under Section 4(a)(2) of the Act, and Regulation D promulgated thereunder. The offer and sale
of the Private Placement Warrants and the shares of common stock underlying such warrants have not been registered under the Securities
Act, or applicable state securities laws. The Company is filing this prospectus with respect to the resale of the shares of common
stock underlying the June 2020 Warrants issuable upon exercise of such June 2020 Warrants. The H.C. Wainwright Warrants and the
underlying shares of common stock may not be offered or sold in the United States, except pursuant to an effective registration
statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities
laws.
II-
2
January 2019 Private
Placement
The
Company entered into an agreement, dated January 30, 2019, by and among the Company and Zhejiang Youchuang Venture Capital Investment
Co., Ltd ("ZYVC") and another partner (collectively, the "JV Partners"), as amended by the Amendment to
the Joint Venture Agreement, dated April 30, 2019 (as amended, the "JV Agreement")
to establish Exoskeleton
Intelligent Robotics Co. Limited (the "China JV"), a Chinese limited liability company designed to develop and serve
the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center in the Zhejiang
Province of China. In connection with the JV Agreement, the
JV Partners agreed to purchase the Company's
common stock in two tranches for
an aggregate of $10 million.
The JV Partners completed the first tranche of their purchase on
January 30, 2019, in which
the Company sold 204,499 shares of its common stock for $5,000,000 at a purchase price of $24.45 per share. The second tranche
for the remaining
$5,000,000
investment by the China JV or
ZYVC
or
its designees is contingent upon the China JV shipping the first batch of EksoGT, EksoVest and EksoZeroG Arm products to Ekso Bionics,
its affiliates or a third party. Pursuant to the JV Agreement, the investment is to be made within 30 business days of the China
JV delivery the first batch of finished EksoGT products to a buyer, through the purchase of shares of the Company's common stock
at a per share price equal to the volume weighted average of the closing price of the Company's common stock on the Nasdaq
Capital Market for the twenty (20) days prior to the date of issuance, provided that such purchase price per share shall be no
less than $19.50 and no more than $29.40.
The Company is relying on the exemption from the registration requirements of
the Securities Act, afforded by Regulation S promulgated thereunder.
In
connection with the CFIUS investigation noted above under "Risk Factors—Risks Related to Our Business," the Company
does not expect the second tranche of the investment to be completed, as it is very likely that our China JV will be terminated
and the shares acquired in connection with the China JV to be divested, including the first tranche of the investment.
2017 Information
Agent Warrants
On
September 13, 2017, in connection with a rights offering in August 2017, the Company entered into an amendment to the information
agent agreement between the Company and Katalyst Securities LLC ("Katalyst") dated August 11, 2017 (the "Information
Agent Agreement"). Pursuant to the amendment, the Company agreed to issue to Katalyst, or its designee, warrants to purchase
an aggregate of 13,333 shares of the Company's common stock at an exercise price of $22.50 per share (the "2017 Information
Agent Warrants"). The 2017 Information Agent Warrants were immediately exercisable upon issuance and will expire three years
from the date of issuance, or September 13, 2020. The 2017 Information Agent Warrants were issued to Katalyst as compensation
for its services as information agent in connection with the Company's 2017 rights offering in lieu of the $200,000 in cash
compensation that would otherwise have been payable to Katalyst pursuant to the Information Agent Agreement. The Company issued
the 2017 Information Agent Warrants and will issue the shares of common stock issuable upon exercise of the 2017 Information Agent
Warrants in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act.
Item 16. Exhibits and Financial Statement Schedules.
See the Exhibit Index
immediately preceding the signature page hereto, which is incorporated in this Item 16 by reference.
Item 17. Undertakings.
(a) 	The
undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the
maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration
statement; and
II-
3
(iii)
To include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or any material change to such information in the
registration statement;
provided
,
however
,
that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-3 or Form F-3
and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with
or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement.
(2)
That, for the purpose of determining any liability under
the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering.
(4)
That, for the purpose of determining liability under
the Securities Act of 1933 to any purchaser:
(i)
Each prospectus filed pursuant to Rule 424(b) as part of the registration statement relating to
an offering, other than registration statements relying on Rule430B or other than prospectuses filed in reliance on Rule 430A,
shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant
to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.
II-
4
EXHIBIT INDEX
The following exhibits
are being filed with or incorporated by reference in this registration statement:
Incorporated
    by Reference
Exhibit
No.
Description
Form
Filing Date
Exhibit
No.
Filed
    Herewith
2.1
Agreement
    and Plan of Merger and Reorganization, dated as of January 15, 2014, by and among the Registrant, Acquisition Sub and
    Ekso Bionics, Inc.
8-K
01/23/14
2.1
4.1
Articles
    of Incorporation of the Registrant
10-K
03/19/15
3.1
4.2
Certificate
    of Amendment of Certificate of Incorporation of Ekso Bionics Holdings, Inc.
8-K
12/27/17
3.1
4.3
Certificate
    of Amendment to the Articles of Incorporation
8-K
03/24/19
3.1
4.4
By-Laws
    of the Registrant
8-K
01/23/14
3.4
4.5
Certificate
    of Merger of Ekso Bionics, Inc., with and into Acquisition Sub, filed January 15, 2014.
8-K
01/23/14
3.3
4.6
Form of
    specimen certificate
S-3
06/23/15
4.4
4.7
Certificate
    of Change of Ekso Bionics Holdings, Inc. effective May 4, 2016
8-K
05/05/16
3.1
4.8
Certificate
    of Amendment to Certificate of Designation of Series A Convertible Preferred Stock, filed on April 4, 2016
8-K
04/07/16
3.1
4.9
Form of
    2015 Warrant
8-K
12/24/15
4.1
4.10
Form of
    Amendment to 2015 Warrant
8-K
03/11/19
99.2
4.11
Form of
    May 2019 Warrant
8-K
05/24/19
4.1
4.12
Form of
    December 2019 Warrant
8-K
12/20/19
4.1
4.13
Form of
    December 2019 Placement Agent Warrant
8-K
12/20/19
4.2
4.14
Form of
    June 2020 Warrant
8-K
06/10/20
4.1
4.15
Form
    of H.C. Wainwright Warrant
8-K
06/10/20
4.2
4.16
Registration
    Rights Agreement
8-K
07/25/17
10.2
4.17
Form of
    Senior Trust Indenture
S-3
06/16/20
4.20
4.18
Form of
    Subordinated Trust Indenture
S-3
06/16/20
4.21
4.19
Form of
    Senior Debt Security
S-3
06/16/20
4.20
4.20
Form of Subordinated Debt Security
S-3
06/16/20
4.21
5.1
Opinion of Snell & Wilmer L.L.P.
X
10.1
Form of Registration Rights Agreement
8-K
01/23/14
10.10
10.2
†
Amended
    and Restated 2014 Equity Incentive Plan
DEF 14A
04/20/19
Appendix A
10.3
†
Form
    of Director Option Agreement under 2014 Equity Incentive Plan
8-K
01/23/14
10.3
10.4
†
Form
    of Employee Option Agreement under 2014 Equity Incentive Plan
8-K
01/23/14
10.14
10.5
†
Form
    of Employee Restricted Stock Unit Award under 2014 Equity Incentive Plan
10-Q
08/07/17
10.46
10.6
†
2017
    Employee Stock Purchase Plan
DEF 14A
04/28/17
Appendix A
10.7
†
Jack
    Glenn Offer Letter dated July 24, 2018
8-K
08/13/18
10.1
10.8
†
Jack
    Glenn Employment Agreement effective August 13, 2018
8-K
08/13/18
10.2
10.9
†
Steven
    Sherman Offer Letter dated October 30, 2018
8-K
11/05/18
10.1
10.10
†
Jack
    Peurach Employment Agreement dated August 7, 2018
10-Q
11/07/18
10.3
10.11
†
*
Jason
    Jones Offer Letter dated September 19, 2018
10-K
02/27/20
10.11
10.12
†
William
    Shaw Offer Letter dated April 2, 2019
8-K
05/06/19
10.1
10.13
Exclusive
    License Agreement, dated as of November 15, 2005, by and between The Regents of the University of California and Berkeley
    ExoTech, Inc., d/b/a Berkeley ExoWorks
8-K
01/23/14
10.19
10.14
Exclusive
    License Agreement, dated as of July 14, 2008, by and between The Regents of the University of California and Berkeley ExoTech,
    Inc., d/b/a/ Berkeley Bionics and formerly d/b/a Berkeley ExoWorks (as amended by Amendment #1 to Exclusive License Agreement,
    dated as of May 20, 2009, by and between The Regents of the University of California and Berkeley Bionics)
8-K
01/23/14
10.20
10.15
*
Government
    Field Cross License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation
8-K
03/31/14
10.25
10.16
*
Medical License Agreement dated as of July
    1, 2013 between Ekso Bionics and Lockheed Martin Corporation
8-K
03/31/14
10.26
10.17
*
Cross
    License Agreement dated as of July 1, 2013 between Ekso Bionics and Lockheed Martin Corporation
8-K
03/31/14
10.27
10.18
†
Form
    of Non-Employee Director Indemnification Agreement
10-Q
05/13/14
10.20
10.19
†
Form
    of Executive Officer Indemnification Agreement
10-Q
05/13/14
10.21
10.20
Securities
    Purchase Agreement dated December 23, 2015, between Ekso Bionics Holdings, Inc. and each purchaser thereto
8-K
12/24/15
10.1
10.21
Form
    of Amendment to Securities Purchase Agreement
8-K
04/07/16
10.1
10.22
Form of Amendment to Purchase Agreement
8-K
03/11/19
99.1
10.23
Form
    of Waiver of Subsequent Equity Sale Prohibition
8-K
08/21/18
99.1
10.24
Purchase
    Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities
    II LLC
8-K
07/25/17
10.1
10.25
Registration
    Rights Agreement, dated as of July 19, 2017, by and between Ekso Bionics Holdings, Inc. and Puissance Cross-Border Opportunities
    II LLC
8-K
07/25/17
10.2
10.26
Form
    of Securities Purchase Agreement
8-K
12/20/19
10.1
10.27
Lease, dated November 29, 2011, between FPOC,
    LLC and Berkeley Bionics, Inc dba Ekso Bionics
8-K
01/23/14
10.21
10.28
First
    Amendment to Lease Agreement, dated March 28, 2012, between FPOC LLC and Berkeley Bionics, Inc. DBA Ekso Bionics, Inc.
10-K
02/27/20
10.28
10.29
Second
    Amendment to Lease Agreement dated November 5, 2016, between FPOC, LLC and Ekso Bionics, Inc.
10-Q
09/20/16
10.38
10.30
Loan
    and Security Agreement dated as of December 30, 2016 by and among the Registrant, Ekso Bionics, Inc. and Western Alliance
    Bank
8-K
01/06/17
10.1
10.31
Success
    Fee Agreement dated as of December 30, 2016 by and among the Registrant, Ekso Bionics, Inc. and Western Alliance Bank
8-K
01/06/17
10.1
10.32
First
    Amendment to Loan and Security Agreement, dated as August 3, 2017, by and among EKSO Bionics Holdings, Inc., EKSO Bionics,
    Inc. and Western Alliance Bank
10-Q
08/07/17
10.48
10.33
Second
    Amendment to Loan and Security Agreement, dated April 29, 2020, by and between Western Alliance Bank, Ekso Bionics Holdings,
    Inc. and Ekso Bionics, Inc.
10-Q
04/30/20
10.1
10.34
Agreement
    for Consulting Services between Ekso Bionics Holdings, Inc and Angel Pond Capital, LLC, dated July 2017
10-K
02/28/19
10.36
10.35
*
Equity
    Joint Venture Contract, dated January 30, 2019, by and among Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned
    subsidiary of Ekso Bionics Holdings, Inc., Zhejiang Youchuang Venture Capital Investment Co., Ltd. and Shaoxing City Keqiao
    District Paradise Silicon Intelligent Robot Industrial Investment Partnership
10-Q
05/01/19
10.1
10.36
*
Amendment
    to the Joint Venture Contract of Exoskeleton Intelligent Robotics Co. Limited, dated April 30, 2019, by and among Ekso Bionics
    Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary of Ekso Bionics Holdings, Inc., Zhejiang Youchuang Venture Capital
    Investment Co., Ltd. and Shaoxing City Keqiao District Paradise Silicon Intelligent Robot Industrial Investment Partnership
10-Q
08/01/19
10.2
10.37
Share
    Purchase Agreement, dated January 30, 2019, between Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary
    of Ekso Bionics Holdings, Inc. and the parties listed thereto
10-Q
05/01/19
10.2
10.38
Form
    of Securities Purchase Agreement
8-K
06/10/20
10.1
10.39
*
Technology
    License Agreement, dated October 22, 2019, between Ekso Bionics Holdings, Inc., Ekso Bionics, Inc., a wholly-owned subsidiary
    of Ekso Bionics Holdings, Inc. and Eksoskeleton Intelligent Robotics Co. Limited
10-K
02/27/20
10.37
21.1
Subsidiaries of Registrant
10-K
02/27/20
21.1
23.1
Consent of Independent Registered Public Accounting Firm
X
23.2
Consent of
    Snell & Wilmer L.L.P. (included in Exhibit 5.1)
X
24.1
Power of Attorney (contained here on the signature page)
X
†
Management contract, compensatory plan or arrangement.
*
Confidential Treatment portions of this exhibit have
been omitted as permitted by applicable regulations.
II-
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933,
the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1
and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Richmond, California, on July 2, 2020.
EKSO BIONICS HOLDINGS, INC.
Date: July 2, 2020
By:
/s/  Jack Peurach
Jack Peurach
Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned
officers and directors of Ekso Bionics Holdings, Inc., hereby severally constitute and appoint Jack Peurach and John F. Glenn,
and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution in each of them for her or him and in her or his name, place and stead, and in any
and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any
other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under
the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority
to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents
and purposes as she or he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
or any of them or their or her or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and
on the dates indicated.
SIGNATURE
TITLE
DATE
/s/ Jack Peurach
President and Chief Executive Officer
July 2, 2020
Jack Peurach
(
Principal Executive Officer
)
/s/ John F. Glenn
Chief Financial Officer
July 2, 2020
John F. Glenn
(
Principal Financial Officer and Principal Accounting
    Officer
)
/s/
    Steven Sherman
Director and
    Executive Chairman of the Board
July 2, 2020
Steven Sherman
/s/ Marilyn Hamilton
Director
July 2, 2020
Marilyn Hamilton
/s/Charles Li, Ph.D.
Director
July 2, 2020
Charles Li, Ph.D.
/s/ Thomas A. Schreck
Director
July 2, 2020
Thomas A. Schreck
/s/ Stanley Stern
Director
July 2, 2020
Stanley Stern
/s/ Ted Wang, Ph.D.
Director
July 2, 2020
Ted Wang, Ph.D.